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1. Introduction: 
1.1 Non-viral gene transfer: 
Altering or manipulating genes or gene expression has tremendous therapeutic 
potential for the treatment of a variety of inherited or acquired disorders. Gene therapy 
aims at treating diseases by delivering DNA, RNA, antisense or RNAi (double stranded 
RNA) sequences that alter gene expression within a specific cell population, thereby 
manipulating cellular processes and responses. Recent advances in molecular biology 
combined with the culmination of the Human Genome Project have provided a genetic 
understanding of cellular processes and disease pathogenesis (1). Numerous genes 
involved in disease and cellular processes have been identified as targets for therapeutic 
approaches. However, the development of novel therapeutic strategies using these targets 
is dependent on the ability to manipulate the expression of these target genes in the 
desired cell population. 
Gene therapy can manipulate gene expression either in vitro or in vivo. The in vitro 
approach involves genetically modifying cells, which are isolated either from the patient 
or from a donor, that are subsequently implanted into the patient (2). The challenge of 
gene therapy is to develop safe and efficient gene-delivery systems. Viral vectors 
generally provide the most efficient gene transfer. The premise of viral gene delivery is to 
use viruses that have sections of their genome removed to make them replication 
deficient. Within the section that was removed, genes encoding for therapeutic proteins 
can be inserted. Viruses are produced using helper cell lines that create attenuated viruses 
that can efficiently deliver the therapeutic gene but are incapable of replicating in vivo. 
The limited space to insert genes into the viral genome combined with issues associated 
with virus production and safety has inspired the development of non-viral DNA delivery 
systems. Non-viral approaches typically involve plasmids (circular DNA), 
Oligonucleotides (short single stranded DNA or RNA) or RNAi. Plasmid DNA, 
Oligonucleotides and RNAi are generally considered to be safe; however, the gene 
transfer efficiency is significantly less than viral vectors and must be improved for many 
therapeutic applications (3). 
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1.2 Barriers against effective gene delivery: 
 Effective gene delivery requires; that the plasmids, oligonucleotides or RNAi that 
is to be delivered to the desired cell population is efficiently internalized by the cell and 
transported to the appropriate cellular compartment. Though the path is known, many 
barriers exist which limit the efficiency of delivery. Endonucleases present in the extra-
cellular space can degrade non-viral DNA within 30 minutes (4). The inability to cross 
biological membranes, such as the plasma membrane, and the nuclear membrane is due 
to the size and charge density of naked DNA. 
Plasmid DNA is typically 10
3
 to 10
4
 base pairs in length, has a super-coiled 
tertiary structure in aqueous solution, a molecular weight of 10
6 
to10
7
 Daltons, and an 
effective hydrodynamic diameter greater than 100 nm (5). The surface charge density of 
naked DNA, which has zeta potentials ranging from –30 mV to –70 mV, creates 
repulsion between the DNA and the negatively charged cell surface. This large size and 
negative surface charge density most likely limits the uptake of DNA by the cells. 
Delivery systems are being developed to overcome these barriers of stability, size, charge 
density, and bio-distribution. 
1.3 Modes of gene delivery: 
 Various modes of gene transfer had been designed to enhance gene transfer by 
improving (i) the stability of DNA, (ii) the efficiency of cellular uptake and the 
intracellular trafficking or (iii) the bio-distribution of DNA. These modes can be largely 
divided as Mechanical and Chemical methods of gene delivery.  
1.3.1 Mechanical Methods: 
Insufficient contact of inherently highly active nucleic acid delivery systems with 
target cells is a primary reason for their often-observed limited efficacy. Mechanical 
methods of targeting can overcome this limitation and reduce the risk of undesired side 
effects due to non-target site delivery (6). Physical methods such as Electroporation, 
Focused laser, Ballistic (gene gun) approaches are known to enhance gene delivery. New 
generation strategies involving the use of Magnetic field (Magnetofection) have 
revolutionized the efficiency of non-viral gene transfer. As plasmid DNA appears to be a 
safe gene vector system, it seems likely that plasmid with physically enhanced delivery 
will be used increasingly in clinical trials.  
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1.3.1.1 Electroporation: 
Electroporation is a physical process of inducing nanometer-sized transient pores 
in the cell membrane by the application of short duration, high intensity electric field 
pulses to cells or tissues. In this permeabilized state, the membrane can allow passage of 
DNA, enzymes, antibodies and other macromolecules into the cells. The most important 
parameters for effective electroporation are the voltage [V], the length of time the field is 
applied (pulse duration), plasmid concentration and electrodes (7). Over the last two 
decades, electroporation equipments have been undergoing considerable refinement. 
Notably, square wave pulse generators have been constructed. These generators modify 
the exponential pulse to a square pulse, where pulse amplitude and pulse length can be 
independently controlled, which is an important pre-requisite for optimization. 
 
Theory of Electroporation: 
The transmembrane potential induced in a cell by an external field is generally 
described by the equation: 
∆Vm = f Eext r cosθ 
Where, Vm is the transmembrane potential, f a form factor describing the impact of the 
cell on the extracellular field distribution, Eext the applied electric field, r the cell radius 
and θ the polar angle with respect to the external field. Many authors list the value for the 
factor f as 1.5; however, this factor is dependent on a number of different factors (8, 9).  
Electroporation is achieved when ∆Vm > ∆Vs which is the threshold potential. As the 
bilayer membrane is a common feature for eukaryotic cells, ∆Vs is similar for various cell 
types. Experimental and theoretical study described ∆Vs as being 200 mV (10). 
Whereas pore formation happens in the microsecond time frame, membrane resealing 
happens over a range of minutes with variation depending on the electric parameters used 
and on temperature. Intact, function of the cytoskeleton is also of considerable 
importance for pore closure (11) 
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1.3.1.2 Magnetofection: 
This method associates DNA with magnetic nano-particles coated with cationic 
molecules (Magnetofectins). The resulting molecular complexes are then transported into 
cells supported by an appropriate magnetic field. Magnetofection exploits magnetic force 
exerted upon gene vectors to drive them towards and possibly even into, the target cells. 
In this manner, the complete applied vector dose gets concentrated on the cells within a 
few minutes so that 100% of the cells get in contact with a significant vector dose. High 
transfection rate achievable with low vector doses and extremely short process time are 
the major advantages of magnetofection (12, 13) 
Mechanism involved in the cellular uptake of Magnetofectins: 
Magnetofectins are super-paramagnetic iron oxide nano-particles coated with 
gene carriers like cationic lipids, cationic polymers etc., Magnetofection seems to follow 
a similar mechanism as found in the cationic gene carrier coating the nano-particles. The 
presence of the magnetic force leads to a fast accumulation of the complexes on the cell 
surface but not to a traction of complexes into the cells. Magnetic gene vector complexes 
are mainly taken into cells by unspecific endocytosis. However, clathrin-dependent and 
caveoli-mediated uptake, are apparently involved in magnetofection based on the cationic 
gene carrier coating the nano-particles. The extent of involvement of clathrin-dependent 
and caveoli-mediated endocytosis is also cell-line-dependent. (14) 
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Figure 1: Electroporation and Magnetofection: Voltage stimulated transient pore formation 
during electroporation (left). Application of magnetic field in gene transfer (right). 
 
These mechanical techniques are capable of transfecting cells, possibly by 
compromising the integrity of the cell membrane thus allowing entry of DNA into the 
cell. However, the details of the mechanism by which DNA is internalized for the various 
systems are not well understood (15) 
 
1.3.2 Chemical Methods: 
These are materials designed to increase gene transfer function to enhance (i) the 
stability of DNA, (ii) the efficiency of cellular uptake and intracellular trafficking or (iii) 
the bio-distribution of DNA. The most common approach involves the complexation of 
naked DNA with cationic lipids or poly (cationic) polymers that package the DNA for 
effective delivery. This approach typically alters the large negative surface charge on the 
DNA and facilitates internalization by the cell. These packages can also provide 
protection against nuclease activity, targeting of a specific cell population, and efficient 
internalization and intracellular trafficking, all of which can significantly increase gene 
transfer efficiencies. 
1.3.2.1 Cationic Lipids: 
 The most investigated approach for condensing non-viral DNA for efficient gene 
transfer is the use of cationic lipids. Felgner and Bennett for oligonucleotides used 
cationic lipids for the first time to deliver DNA (16). More recently, siRNA has been 
delivered to mammalian cells using commercially available lipids (17, 18, 19). Although 
some cationic lipids are used individually to deliver DNA (e.g., DOTAP), many 
formulations of cationic lipids also contain a zwitterionic or neutral co-lipid, such as 
DOPE or cholesterol, to enhance transfection. Formulations of cationic lipids have been 
widely applied for in vitro nucleic acid transfection and more than 30 products are 
commercially available for this purpose, including Lipofectin (a 1:1 mixture of DOTMA 
and DOPE), Transfectam, Lipofectase, Lipofect-AMINE and LipoTaxi (20). 
 The main components of a cationic lipid are a hydrophilic lipid anchor, a linker 
group, and a positively charged head group. The lipid anchor is typically either a fatty 
acid chain (e.g., derived from oleic or myristic acid) or a cholesterol group, which 
determines the physical properties of the lipid bi-layer, such as flexibility and the rate of 
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lipid exchange (21). The linker group is an important determinant of the chemical 
stability, bio-degradability, and transfection efficiency of the cationic lipid. 
Biodegradable lipids are being developed, which can be metabolized by various enzymes 
(e.g., esterases, peptidases) to minimize toxicity (22, 23). The linker can also provide 
sites for the introduction of novel side chains to enhance targeting, uptake, and 
trafficking. The positively charged head group on the cationic lipid self-assembles with 
the negatively charged DNA and is a critical determinant of the transfection and 
Cytotoxic properties of liposome formulations. The head groups differ markedly in 
structure and may be single or multiple charged as primary, secondary, tertiary or 
quaternary amines. The hydrophobicity of the lipid moiety has a crucial effect on in vitro 
gene transfer. Generally, increase in the linker length corresponds with the increase in 
gene delivery (24). 
 Mixing of DNA and cationic lipid results in the collapse of DNA to form a 
condensed structure, termed lipoplex, in which nucleic acids are buried within the lipid. 
Liposome association with DNA has resulted in tube like bi-layers (25, 26), multi-
lamellar complexes (27, 28, 29), as well as structures containing non bi-layer elements 
(30, 31). These arrangements have demonstrated increased transfection, which is 
attributed to the relative instability of the complexes due to rapid fusion with anionic 
vesicles and subsequent DNA release. 
The colloidal properties (e.g., size, stability) of the lipoplexes are principally 
determined by the cationic lipid/DNA charge ratio and not the composition of the lipid or 
the helper lipid. The charge ratio (+/-) is typically defined as the number of amines on the 
cationic lipid relative to the number of phosphate groups on the DNA. A neutral charge 
ratio (1:1 charge ratio for lipid: DNA) is typically avoided because it results in the 
formation of large aggregates (>1 µm). Lipoplexes prepared at positive charge ratio and 
negative charge ratio likely represents structures with different lipid and DNA packaging 
(32). At a positive charge ratio, large Multi-lamellar vesicles (LMV, diameter 300 - 700 
nm) transfect cells more efficiently (21, 33, 34). The order in which DNA and lipid are 
mixed is critical and significantly affects the lipid and DNA packing (35, 32). When 
adding DNA to lipid, a gradual increase in size was observed. When adding lipid to 
DNA, the particle size remains roughly constant until the amount of lipid’s positive 
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charge exceeds the nucleic acid’s negative charge, whereupon the particles grow rapidly 
in size (35). 
The net charge on the lipoplex affects its interactions with other components 
present in vivo and in vitro (e.g., media, serum, extra-cellular matrix glycoproteins, 
mucosal secretions), which can limit the transfection efficiency. A positive charge ratio, 
which facilitates interactions with the cell membrane, is frequently used for in vitro 
studies (3:1), whereas in vivo studies may require the charge ratio to be altered because of 
interactions with components of the physiological environment (36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structure of common lipids used as materials for gene therapy. Cationic lipids: 
DOTMA:[2,3-bis(oleoyl)propyl]-trimethyl]ammoniumchloride; DMRIE:1,2dimyristyloxypropyl-
3-dimethyl-hydroxyethyl ammonium bromide; DODAB: dioctadecyldimethyl ammonium 
bromide; DOTAP: 1,2-diacyl-3-trimethylammonium propane; DC-Chol: 3[N-(N0,N0-
dimethylaminoethane)-carbamoyl] cholesterol. Neutral Lipids: DOPE: dioleoylphosphatidyl 
ethanolamine; DOPC: dioleoylphosphatidyl choline; Chol: cholesterol. 
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Multivalent anions present in the serum or media can facilitate fusion of the lipids 
causing an increase in the size of the particle. Serum can be a complicating factor for 
positively charged complexes, possibly causing premature release of the DNA from the 
complex and enhancing degradation by nucleases. For oligonucleotide + lipid complexes, 
the various components of serum (e.g., BSA, lipoproteins, macroglobulin) interact with 
the complexes and alter the complex diameter, zeta potential, and interfere with cellular 
uptake and nuclear trafficking (37). Therefore complexation is generally performed in a 
serum free medium. 
Aggregation of lipoplexes occurs rapidly, which may result in loss of activity in 
less than 24 hours. Thus, strategies are being developed to stabilize the particles and 
prolong their shelf life. To improve lipoplex stability, poly-ethylene-glycol (PEG) has 
been incorporated into the cationic liposome. PEG containing liposomes are prevented 
from aggregating and interacting with serum components, which increases their stability 
(38, 39, 40). 
1.3.2.2 Cationic Polymers: 
 Cationic polymers have been used since the late 1980’s (41) as materials for gene 
delivery. Cationic polymers contain high densities of primary, secondary, tertiary or 
quaternary amines, some of which are protonatable at neutral pH. This high density of 
positive charges allows the cationic polymers to form stable complexes with DNA. The 
cationic polymers assemble with DNA in order to generate condensed structures (40 – 
1000 nm in diameter) capable of entering the cell. In addition to providing positive 
charges for DNA complexation, the primary amines also serve as functional groups to 
chemically modify the polymers with ligands and peptides that can enhance one or more 
of the steps in the transfection process. 
Poly-L-Lysine: 
Poly-L-lysine (PLL) is one of the most commonly used cationic poly amino acids 
for gene delivery. PLL is typically used at charge ratios (+/-) ranging from 3:1 to 6:1. As 
increasing amounts of PLL are added to DNA, the structure changes from circular to 
thick, flattened to compact, and finally to toroid and rod like at a charge ratio of 6:1 (42). 
The diameter and cross section of the toroids are approximately 140 nm and 44 nm 
respectively. The ideal length of the PLL represents a balance between effective 
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condensation and Cyto-toxicity. Compared to the low molecular weight PLL, the high 
molecular weight PLL forms tighter, smaller condensates that are more resistant to the 
effects of salt concentration and sonication (43). However, Cyto-toxicity is inversely 
related to particle size (44). Variation for this exists in case of linear PLL / DNA 
complexes. Additional information can be found somewhere else (45). 
 
 
 
  
 
 
 
 
 
 
Recent work with poly-amino acids (PAA) focuses on modifications to make 
them more suitable for gene therapy. For example, the addition of PEG to PLL has shown 
that PEGylated PLL forms mono-disperse complexes of approximately 25-125 nm in 
diameter (46). PLL was also used in combination with liposomes. DNA is initially 
complexed with PLL at low charge ratios and cationic lipids are subsequently added to 
completely condense the DNA. Alternatively, the PLL condensed DNA containing a net 
positive charge can subsequently be complexed with an anionic lipid (47). Pre 
condensation with PLL has been shown to reduce serum inhibition and also enhance the 
transfection efficiency (48, 49). 
Poly Ethylene Imine: 
 Poly Ehylene Imine (PEI) is perhaps the most widely used cationic polymer to 
mediate gene delivery due to its high cationic charge density resulting from the 
protonatable amine on every second carbon (50). Its high efficiency of transfection has 
resulted in two commercially available transfection products ExGene™ and jetPEI®. PEI 
is synthesized using the acid catalyzed ring opening polymerization of aziridine as either 
a linear or a branched structure (51). Similar to the PLL complexes, low molecular 
 Poly(lysine) 
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weight PEI is less Cyto-toxic than high molecular weight PEI. Furthermore, PEI-DNA 
complexes must also bear a net positive charge (4-13:1 +/- ratio) in order to efficiently 
transfect cells (50, 52, 53). PEI-DNA complexes form spheres or toroids with mean 
diameters ranging from 30 to 100 nm. The presence of NaCl during complexation can 
result in particles with amorphous shapes and diameters greater than 1µm. 
PEG is used in order to prevent non-specific DNA-cationic polymer complex interactions 
with serum proteins, cells and tissues in the body, to increase the solubility of the 
complexes in aqueous milieu, and to prevent the interaction between the DNA-cationic 
polymer complexes and limit their aggregation in solution (54). Traditional cationic 
polymers for gene delivery such as PEI and PLL have been made more biocompatible 
using this approach (54, 55, 56). Although PEI is one of the most efficient synthetic 
cationic polymers for gene delivery to date, it is not biodegradable and can have 
significant Cyto-toxicity both in vitro and in vivo. In an effort to increase the 
biocompatibility of PEI, low molecular weight PEI was cross-linked with degradable 
PEG polymer (55). Low molecular weight PEI was cross-linked with di-functional PEG 
to form PEI-PEG-PEI. The molecular weights of the starting PEI polymers were 600, 
1200, 1800 Da, while the molecular weight of the di-functional PEG derivative was kept 
constant. Cyto-toxicity experiments showed decreased Cyto-toxicity for complexes 
formed with degradable PEI/DNA complexes when compared to complexes formed with 
25kDa PEI.  
 
 
 
 
 
 
 
 
 
 
 
PEI – PEG - PEI 
PEI 
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1.4 Peptides in gene delivery:  
1.4.1 Arginine (Arg) rich peptides in gene delivery: 
 Recently, methods have been developed for the delivery of exogenous proteins 
into living cells with the help of membrane permeable carrier peptides. By genetically or 
chemically hybridizing these carrier peptides, efficient intracellular delivery of various 
oligopeptides and proteins was achieved. The use of HIV-1 Tat (48-60) and Drosophila 
Antennapedia (43-58) in delivering peptides (β-galactosidase) and fluorescence probes to 
various tissues in mice including the brain, augments their use as tools not only in 
therapeutic purposes but as an alternative to gene delivery (57, 58). Besides HIV-1 Tat, 
Antennapedia and Herpes simplex virus type-1 VP22 transcription factor, various RNA 
binding, DNA binding proteins and simply poly-Arginines (R4 to R16) are used in various 
studies. 
 
RNA-binding peptides: 
HIV-1 Rev (34-50) 
FHV(floch house virus) coat (35-49) 
BMV(brome mosaic virus) Gag (7-25) 
HTLV-II(human tcell lymphotropic)Rex(4-
16) 
λN(1-22) 
Ø21 N (12-29) 
Yeast PRP6 (129-144) 
 
TRQARRNRRRRWRERQR 
RRRRNRTRRNRRRVR 
KMTRAQRRAAARRNRWTAR 
TRRQRTRRARRNR 
MDAQTRRRERRAEKQAQWKAAN 
TAKTRYKARRAELIAERR 
TRRNKANRIQEQLNRK 
DNA-binding peptides: 
Human c-Fos (139-164) 
Human c-Jun (252-279) 
Yeast GCN4 (231-252) 
 
KRRIRRERNKMAAKSRNRRRELTDT 
RIKAERKRMRNRIAASKSRKRKLERIAR 
KRARNTEAARRSRARKLQRMKQ 
 
Table 1: Arginine rich peptides: Number of Arg decreases down the table in each type and so 
does their internalization efficiencies 
 
 Arg rich basic segments are used by a variety of RNA binding proteins to 
recognize specific RNA structures. Futaki. S et al., showed that peptide translocation 
through the cell membrane and accumulation in cytoplasm and nucleus showed a 
tendency to correspond to the number of Arg residues in the sequence. Similar effects 
were also observed with the DNA-binding peptides corresponding to the basic Leucine 
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zipper segments derived from cancer related proteins (c-Fos, c-Jun) and yeast GCN4, 
which were also rich in Arg. There seems a common or very similar mechanism for the 
internalization among these peptides. The mechanism is explained neither by adsorptive 
mediated nor receptor mediated endocytosis, because the peptides were shown to have 
internalized by cells at 4
o
C, and there seemed little homology both in the primary and 
secondary structures among these peptides (as shown by their Circular Dichroism 
spectra) except that they have several Arg residues in their sequence. Studies on 
application of poly-Arginines (R4 to R16) suggest that an optimal number of Arg residues 
(6-10) are required for efficient internalization. There still remains a question why such 
efficient translocation is possible for Arg rich peptides? Possible hydrogen bond 
formation with lipid phosphates or interaction with extra-cellular matrices such as 
heparin sulphate may be involved in the initial steps during the mechanism. However, 
failure of internalization of peptides >R10 residues suggest that it is not enough to explain 
the mechanism only by considering adsorption of peptides on the membranes (59). 
  1.4.2 Tat (Transcriptional activator protein): 
 The HIV-1 (Human immunodeficiency virus type1) is a retrovirus belonging to 
the Lentiviridae family. The genome of most retrovirus encodes the conserved structural 
and enzymatic genes encoding the Gag, Pol and Env proteins. In addition to these, HIV-1 
contains two additional regulatory genes (tat and rev) and four accessory genes (vif, vpu, 
vpr, and nef). These additional genes differentiate lentivirus from oncovirus.  
 
 
 
 
 
Figure 3: Wild type HIV-1 genome organization. 
 
 Tat is a transcriptional activator that binds to a short nascent stem-bulge-loop 
leader RNA, TAR (trans-activation responsive), for its activity. The 101-amino acid Tat 
protein, with residues 1–72 encoded by a first exon and residues 73–101 encoded by a 
second exon, can be arbitrarily considered as containing several “domains” of interest. It 
should be noted that an 86 amino acid form of Tat exists in a few laboratory passaged 
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virus strains (e.g. LAI, HXB2, pNL4–3). These versions represent a truncated and non-
natural full-length protein. Although residues 87–101 of Tat might not contribute greatly 
to the ex vivo propagation of HIV-1, their conservation in viruses that replicate in vivo 
provides a good indication of their biological importance. (60) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Physical domains of the 101-amino acid HIV-1 Tat protein. Tat can be broadly 
viewed as containing five physical domains. The underlying illustration highlights that the 
popularly considered full-length Tat protein (86 amino acids) based on the open reading frames 
from laboratory passaged viruses (LAI, HXB2, and NL4–3) is likely missing for the carboxyl-
terminal 87–101 amino acid residues, which are conserved in natural isolates of HIV-1 that 
replicate in vivo. Thus it has been shown that a single nucleotide change in the stop codon of Tat 
from laboratory isolates, LAI, HXB2, and NL4–3, converts these open reading frames to the 101-
amino acid sequence (e.g. SF2) found in Tat from natural viral isolates. 
 
  
The best-studied region of Tat resides in amino acids 49–72 (domain 4), which 
contain a basic RKKRRQRRR motif. This peptide motif confers TAR RNA binding 
properties to Tat (32–35), which is important for the nuclear localization and uptake of 
Tat by the cells. For association with TAR, the short basic motif contributes importantly 
to affinity but dictates insufficiently to the specificity of binding. Flanking amino acids 
outside this basic domain significantly influences the specificity of Tat-TAR interaction. 
(60) 
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1.4.2.1 Role of Tat in HIV-1 LTR- directed transcription: 
 Transcription from the HIV-1 LTR is several hundred folds higher in the presence 
of Tat than in its absence. Optimal Tat action requires in addition to TAR RNA, basal 
(TATA) and upstream promoter elements (e.g. Sp1). In considering Tat action, one 
should understand that two operationally defined events occur for each round of 
transcription at virtually all promoters. These are: (i) recruitment of an RNA polymerase 
II (RNAP II) complex to the promoter and (ii) the escape of that complex from the 
promoter into productive elongation. Several models of Tat transactivation have been 
proposed. The following are the two widely accepted ones. (60) 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Schematic models of Tat transactivation: A simplified representation of the HIV-1 
promoter containing two (small yellow rectangles) NF-kB-binding sites and three (small yellow 
ovals) Sp1-binding sites. Large ovals represent RNAP II complexes that overlie the TATAA box 
and transcribe a promoter-proximal stem-bulge-loop TAR RNA. Tat (gray) binds the bulge of 
TAR, whereas TAK (purple) binds the loop of TAR. In A, loop-bound TAK is shown to 
phosphorylate RNAP II in its CTD domain converting a non-processive (red) to a processively 
elongating (green) polymerase. Here, it is suggested that TAK acts on a paused RNAP II 
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molecule which has cleared the promoter. B diagrams an alternate view whereby protein(s) bound 
to the TAR loop of an early elongating RNAP II affects the activity of a subsequent RNAP II that 
is yet docked at the promoter, converting a non-productive (red) to a productive (green) complex. 
In this perspective, an activity of TAR-bound proteins serves to facilitate promoter clearance. The 
activities in A and B need not be mutually exclusive. 
 
1.4.2.2 Role of Tat in cellular uptake: 
 Several studies have shown that exogenous Tat protein was able to translocate 
through the plasma membrane and to reach the nucleus to trans-activate the viral genome. 
A region of the Tat protein centered on a cluster of basic amino acids has been assigned 
to this translocation activity. Recent data have demonstrated that chemical coupling of a 
Tat derived peptide (37-72 of domain 4) to several proteins allowed their functional 
internalization into several cell-lines or tissues. A part of this domain can be folded in a 
α-helix structure with amphipathic characteristics. Such helical structures have been 
considered as key determinants for the uptake of several enveloped viruses by fusion or 
endocytosis (61, 62, 57). Rudolph. C et al., have shown that oligomers of Tat peptide, 
compacts plasmid DNA to nanometric particles and stabilizes the DNA from nuclease 
degradation (63). Recent data have shown that, HIV-1 virus itself or full-length Tat may 
exploit a caveoli-mediated pathway for cellular internalization and is inhibited at 4
o
C. 
The exact pathway(s) of Tat peptide resulting in nuclear localization is however 
unexplained. (64, 65) 
     
1.4.3 Integrin-targeting: 
 RGD has high affinity towards integrin receptors - αVβ3, α5β1 expressed on cell 
surfaces and therefore may improve DNA binding to cells. Albinsson. B et al., studies on 
Adenovirus type 41 lacking an RGD alpha (v)-integrin binding motif on the penton base, 
showed a delayed uptake in A549 cells. Various studies in different cells have shown an 
enhancement of integrin-mediated transfection with synthetic vector systems containing 
RGD motifs (66) 
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S.No Integrin target Sequence 
1 
2 
α3I, α5β1, αVβ3, αVβ5, αIIBβ3 
α5β1 
GACRGDMFGCA 
GACRRETAWACG 
 
Table 2: Peptide sequences and receptor targets. 
  
 Integrins are a family of more than 20 heterodimeric membrane proteins that bind 
to extracellular matrix proteins. Integrins play an important role in cellular activities such 
as cell-cell interactions, attachment of the cells to the basement membrane and cell 
motility. A diverse range of pathogens, including bacteria and viruses, exploits Integrin 
receptors, for their cell binding and entry. On this basis it was proposed that integrin-
targeting might also be an efficient pathway for the uptake of synthetic gene delivery 
vehicles. Cellular distribution patterns of the 20 or so known heterodimers vary, with 
some, being wide spread in their cellular distribution such as α3β1 and others being more 
restricted, such as αMβ2 which occurs on macrophages only. Integrin expression and 
activation patterns may be altered in disease processes such as lung inflammation, 
cancers, allowing further specific targeting opportunities. Exogenous agents such as 
cytokines and phorbol esters may activate some integrins, including the fibronectin 
receptors α4β1 and α5β1. Activated integrins have higher ligand-binding affinity, which 
therefore may enhance the efficiency of vectors targeted to these integrins (67). 
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1.5 Application: RELM-β as hypoxia induced mitogenic factor. 
 Pulmonary vascular remodeling, characterized by pulmonary micro-vascular 
smooth muscle cell proliferation, is implicated in the development of hypoxic pulmonary 
artery hypertension (PAH). Broncho-alveolar lavage (BAL) fluid from mice with 
experimentally induced allergic pulmonary inflammation revealed a novel 9.4 kDa 
cysteine rich secreted protein, FIZZ1 (found in inflammatory zone) (68). 
FIZZ1 is a recently described protein in rodents, and belongs to a novel class of cysteine 
rich proteins known as the FIZZ family. The murine FIZZ genes are expressed in distinct 
tissue specific patterns, implying divergent biological activities. Murine FIZZ2 (mFIZZ2) 
is found exclusively in the actively replicating crypt epithelium of the small and large 
intestine. Murine FIZZ3 (mFIZZ3) is expressed uniquely in white adipose tissue through 
out the body. Murine FIZZ1 (mFIZZ1) is expressed in at least two tissues: the lung 
epithelium and non-neuronal cells adjacent to neurons, particularly in the submucosa of 
the gut and peribronchial stroma. In lung mFIZZ1 expression is specific to bronchial 
mucosal epithelial cells and type II alveolar pneumocytes. Increased expression in 
bronchial epithelial and type II pneumocyte, in allergen-induced inflammation suggests 
the role of mFIZZ1 in respiratory epithelial cell maintenance and response to injury (68). 
Although human FIZZ2 and FIZZ3 have been reported, there is yet no known human 
homologue of FIZZ1 (69). 
FIZZ3 was shown to be implicated in type II diabetes mellitus and was renamed as 
resistin (70). FIZZ1 and FIZZ2 were renamed as resistin-like molecule α (RELMα) and β 
(RELMβ) respectively. Resistin shows no significant sequence identity to previously 
characterized proteins and exhibits similarity only to the other family members, RELMα, 
RELMβ and the recently discovered RELMγ. Phylogenomics revealed that the human 
resistin gene is the ortholog of its murine counterpart and is located in a region of 
chromosome 19p13.3, which is syntenic to mouse chromosome 8A1. In addition to the 
RELM sequences already reported, bioinformatic analysis disclosed another RELM 
sequence in the vicinity of RELMβ on human chromosome 3q13.1, but this sequence is 
unlikely to encode an expressed gene. Therefore, only two RELMs- resistin and RELMβ, 
exist in humans, instead of the three RELMs- resistin, RELMα, and RELMβ that exist in 
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mice. This study suggests that the RELM family is not well conserved in evolution and 
may function differently between species (71). 
 Xingwu Teng et al., hypothesized that mFIZZ1 participates in the process of hypoxia-
induced pulmonary remodeling. mFIZZ1 could be induced at or near the pulmonary 
vasculature by hypoxia, and the secreted mFIZZ1 might have a proliferative effect on the 
pulmonary vascular smooth muscle cells. mFIZZ1 was found to be markedly induced by 
hypoxia in the pulmonary vasculature as well as in bronchial epithelial cells and type II 
pneumocytes. mFIZZ1 was shown to stimulate pulmonary smooth muscle cell 
proliferation, and so it was renamed as hypoxia induced mitogenic factor (HIMF) (72). 
Recent studies have shown that HIMF expression is induced in compensatory lung 
growth and that intra-tracheal instillation of HIMF protein induced wide spread cell 
proliferation in mouse lung (73). 
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Aim of the work: 
Efficient DNA transfection is critical for biological research and new clinical therapies. 
Current non-viral transfection methods, empirically designed to maximize DNA 
complexation and/or membrane fusion, are amenable to enhancement by a variety of 
chemicals. Most chemical enhancements produce a moderate increase in gene delivery 
and a limited increase in gene expression, which is a primary requisite for various studies. 
Further more, the toxicity associated with these agents also circumscribe their utility 
especially on primary cells. In the present study we employed a synthetic conjugate 
peptide TatRGD (TR) as a vehicle for gene delivery in pulmonary cell-lines and primary 
cells. We applied these vectors to study the role of RELMβ as hypoxia induced mitogenic 
factor 
Specific Aim 1: Generation of non-viral gene transfer mode for pulmonary cell-line and 
primary cells, with vector systems containing synthetic conjugate peptide, TatRGD and 
observing the role of caveoli in the cellular internalization of these vectors. To meet this 
aim the following approaches were undertaken: 
1. Synthesis of conjugate peptide TatRGD following F-moc strategy and HPLC 
purification. 
2. Analysis of TR and DNA binding. 
3. Particle size measurements for TRD (TatRGD/ DNA) and TRDL (TatRGD/ 
DNA/ cationic Lipid) using zeta sizer. 
4. Cyto-toxicity assays for TRD and TRDL vectors. 
5. Dosage optimisation for TRD and TRDL vectors. 
6. Analysis of DNA uptake using gene scan. 
7. Comparison of transfection efficiencies of TRDL vectors with that of other 
commercial transfection agents employed. 
8. Analysis of the role of Caveoli in the cellular internalization of TRDL vectors 
employing immuno-staining and laser scanning confocal fluorescence 
imaging techniques. 
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Specific Aim 2:  Application of TR mediated gene transfer in studying the role of RELMβ 
as a candidate gene responsible for pulmonary vascular cell proliferation or in hypoxia 
related fibrotic lung diseases. To meet this aim the following approaches were 
undertaken.  
1. Isolation and cloning human RELMβ cDNA from human lung tissue. 
2. Expression analysis of RELMβ in various human tissues. 
3. Regulation of RELMβ in A549, FBPA and SMCPA cells by semi-quantitative and 
quantitative RT-PCR. 
4. Over-expression of RELMβ employing TRDL and DL vectors and subsequent 
analysis by western blotting and proliferation assays. 
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2.1 Materials: 
2.1.1 Cell biology materials:  
2.1.1.1 Cells:  
A549 (Human Caucasian lung carcinoma cells): A549 cells are derived from a 58 year 
old Caucasian male. These cells can synthesise lecithin utilising the cytidine 
diphosphocholine pathway. Occasionally, cells may also contain inclusion bodies 
although they are not known to carry any human pathogen.  
Morphology: Epithelial. Depositor: Obtained from ATCC, USA. 
FbPA (Human pulmonary artery fibroblast cells) and SMCPA (Human pulmonary artery 
smooth muscle cells):  Primary cells were isolated from the human pulmonary artery. 
Human primary cell preparations were established from lung tissue obtained from 
patients undergoing lung transplantation with their due consent. This protocol was 
approved by the Justus-Liebig-University ethics committee.  Cells of passage 2 and 3 
were used.  
2.1.1.2 Cell culture: 
OptiMEM + glutaMAX (GIBCO) 
Trypsin 1x: It is a proteolytic enzyme. Trypsin usually in combination with EDTA; 
causes cells to detach from the growth surface. The proteolysis reaction can be quickly 
terminated by the addition of complete medium containing serum. 
 
Component Volume 
Trypsin 10x 10 ml 
200mM HEPES 10 ml 
0.9% NaCl 80 ml 
Total 100 ml 
 
 
Culture Medium: 
 
Medium Components A549  FbPA and SMCPA 
Medium DMEM(F12)Nutrient Mix MCDB 131 
Antibiotic (Pen-Strep) 1% 1% 
Glutamine 1% 1% 
Non-Essential A.a 1%  
EGF  0.5ng/ml 
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BFGF  2ng/ml 
Insulin  5µg/ml 
Vitamins 1%  
FCS 10% 5% 
 
 
Table 3: Medium composition for A549, FBPA and SMCPA cells. 
 
2.1.1.3 Transfection agents:  
Magnetofections reagent (Chemicell): CombiMAG/L-200 is a ready to use 
magnetofection reagents. It can be combined with any poly-cationic and lipidic 
transfection reagent, and also with adenoviral and retroviral vectors. 
MagnetoFACTOR plate (Chemicell): Apart from suitable magnetic nano-particles, 
magnetofection requires appropriate magnetic fields. These are provided by the 
MagnetoFACTOR plate, especially designed for magnetofection.  
 
Polyethylenimine (PEI), high molecular weight, water-free (ALDRICH): PEI is a 
branched polymer. Average molecular weight: 25,000. Density: 1.03g/ml at 25
O
C.  
      Formula: 
 
 
 
LipofectamineTM 2000, 1mg/ml (Invitrogen): LipofectamineTM 2000 is a cationic lipid 
suitable for the transfection of nucleic acids into eukaryotic cells. Use of LipofectamineTM 
2000 provides high transfection efficiency in many cell types and formats (e.g. 96-well). 
It can be added directly to cells in culture medium (in presence or absence of serum). 
Complexes can be removed after 4-6 hours without loss of activity. 
  
TatRGD Conjugate peptide diluted to 2mg/ml. 
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2.1.2 Molecular biology materials:  
2.1.2.1 Bacterial strains: 
TOP10 bacterial strain from Invitrogen was used for plasmid transformation. Genotype of 
the strain is “F-mcrA. (mrr-hsdRMS-mcrBC) Φ80lacZ. M15. lacX74 recA1 araD139. 
(araleu) 7697 galU galK rpsL (StrR) endA1 nupG ” 
 
2.1.2.2 Vectors: 
pGL3-CMV vector: The pGL3-basic vector was used for obtaining pGL3-CMV vector. 
The CMV fragment was cloned using Sal I and BamH I restriction sites in pGL3-basic 
vector. Expression of luciferase activity in cells transfected with this plasmid is due to 
proper orientation of CMV promoter upstream from luc+. This vector also contains 
ColE1 ori, f1 ori, ampicillin resistance gene and MCS. 
pEGFP Vector: pEGFP-N1 vector was used for transfecting cells and checking their 
transfection efficiency through the emission of green fluorescence. Plasmid pEGFP-N1 
encodes a red-shifted variant of wild-type GFP (1–3) which has been optimized for 
brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 
488 nm, emission maximum = 507 nm). The MCS in pEGFP-N1 is between the 
immediate early promoter of CMV (PCMV IE) and the EGFP coding sequences. 
pGEM®-T Easy vector: The vector pGEM®-T Easy (Promega, Madison USA) was 
used for the cloning and sequencing of PCR products. The vectors are prepared by 
cutting Promega’s pGEM®-T Easy Vectors with EcoR V and adding a 3´ terminal 
thymidine to both ends. These single 3´-T overhangs at the insertion site greatly improve 
the efficiency of ligation of a PCR product into the plasmids by preventing 
recircularization of the vector and providing a compatible overhang for PCR products 
generated by certain thermo stable polymerase. These polymerases often add a single 
deoxyadenosine, in a template-independent fashion, to the 3´-ends of the amplified 
fragments. It contains ColE1 ori for the replication in E coli, the Ampicillin resistance 
gene for antibiotic selection, f1 ori for single strand DNA production, the LacZ gene 
encoding β-galactosidase which provides the possibility for blue/white color selection of 
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recombinant clones, a multiple cloning site (MCS), T7 and SP6 RNA polymerase 
promoters for DNA sequencing. 
pCMV-HA vector: The pCMV-HA vector was used in the experiments for tagging the 
protein of interest with an HA epitope. This vector also contains ColE1 ori, f1 ori, 
ampicillin resistance gene and HA epitope sequence followed by MCS. 
 
2.1.2.3 Oligonucleotides: 
The oligonucleotides were obtained from Metabion (Martinsried, Germany) at the 
synthesis scale: 0.02 µmol. 
Oligonucleotides for PCR and Cloning: 
 
 
Fam-CMV (400bp) 
Fam CMV- :  5´ Fam- ATG GAA AGT CCC TAT TGG CGT 3´ 
Pgl3 + :  5´ CTG TCC CCA GTG CAA GTG CA 3´ 
 
CMV (400bp) 
CMV- :  5´ ATG GAA AGT CCC TAT TGG CGT 3´ 
Pgl3+ :  5´ CTG TCC CCA GTG CAA GTG CA 3´  
 
RELMβ 
Full length RELMβ (F) (for cloning in pGEM-T easy) 
M-HIMF-f: 5´ AAA CTG AGT TCT CAG CCT CCT C 3´   
P-HIMF-f: 5´ CCC CAG GAC ACT GAC TCT GTA 3´ 
 
RELMβ (for cloning in pCMV-HA) 
HIMF-kozak-kpn1: 5’ ctt ggt acc gcc gcc acc ATG GGG CCG TCC TCT TGC CTC C 3’ 
HIMF-HA-TGA-xho1: 5’ gaa ctc gag tca gcc gcc acc agc gta atc tgg aac atc gta tgg gta 
gcc ACC GGT CAG GTG GCA GCA GCG GGC AGT GGT CC 3’   
 
Oligonucleotides for RT-PCR and Real time RT-PCR: 
 
 
HIMF 
hs HIMF – 362 - :  5´ CCA CGA ACC ACA GCC ATA G 3´ 
hs HIMF – 145+ :  5´ CCC TTC TCC AGC TGA TCA AC 3´ 
 
HPRT 
HPRT –: 5´ TCA AAT CCA ACA AAG TCT GGC CTG T 3´  
HPRT +: 5´ TCG AGA TGT GAT GAA GGA GAT GGG A 3´ 
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Oligonucleotides for Sequencing: 
 
pGEM®-T Easy 
T7:   5´ TAATACGACTCACTATAG 3` 
SP6: 5´ATTTAGGTGACACTATAGAA 3` 
 
pCMV – HA  
Forward:  5´ AGT GTT ACT TCT GCT CTA AAA GCT GC 3´   
Reverse:  5´ CAC TGC ATT CTA GTT GTG GTT TGT 3´ 
 
2.1.2.4 Enzymes: 
Restriction endonucleases: 
All restriction endonucleases were obtained from Roche Diagnostics GmbH, Mannheim, 
Germany. Their activity was optimized in their respective buffers provided by the 
company. The characters of restriction endonucleases were described as follows: 
Enzyme Specificity Buffer 
Enzyme Sequence Buffer 
 
Xho I 
 
 
Kpn I 
 
 
 
5’ C
↓
TCGAG 3’ 
 
 
5’ GGTAC
↓
C 3’ 
 
10mM Tris HCl (pH 8), 5mM MgCl2, 100mM NaCl, 
0.1mg/ml BSA 
 
10mM Tris HCl (pH 7.5), 10mM MgCl2, 0.1mg/ml 
BSA 
 
 
HotstarTaq DNA-Polymerase 
HotstarTaq DNA Polymerase (Qiagen Inc, Hilden, Germany) is a modified form of Taq 
DNA polymerase that is supplied in an inactive state that has no polymerase activity at 
ambient temperatures. This prevents extension of nonspecifically annealed primers and 
primer dimers formed at low temperatures during PCR setup and the initial PCR cycle. 
HotstarTaq DNA Polymerase is activated by 15 min incubation at 95°C that can be 
incorporated into thermal-cycler program. Hotstar Taq DNA polymerase is a 5’-3’ DNA 
polymerase and has no 3’-5’ and 5’-3’ exonuclease activity.  
CIP (Calf Intestinal Alkaline Phosphatase) 
Alkaline Phosphatase catalyzes the removal of 5´ phosphate groups from DNA, RNA, 
ribo and deoxyribonucleoside triphosphates. Since CIP treated fragments lack the 
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5´phosphoryl termini required by ligases, they cannot self-ligate. This property can be 
used to decrease the vector background in cloning experiments. 
T4 DNA ligase 
T4 DNA ligase was purchased from Roche Diagnostics GmbH, Mannheim, Germany. 
This enzyme catalyzes the formation of a phosphodiester bond between the 5' phosphate 
of one strand of DNA and the 3' hydroxyl group of the other. This enzyme is used to 
covalently link or ligate fragments of DNA together. Most commonly, the reaction 
involves ligating a fragment of DNA into a plasmid vector. 
RNase A 
Bovine pancreatic ribonuclease A (RNase A) was also purchased from Roche 
Diagnostics GmbH, Mannheim, Germany. It is a small monomeric enzyme of 124 amino 
acids and a molecular weight of 13.7 kDa. The function of this enzyme is to hydrolyze 
single-stranded RNA by cleaving the phosphodiester bond. It results in formation of 
nucleoside 5’-monophosphates. RNase A has a pH optimum at 7.0 - 7.5 (Sambrook & 
Russell 2001). It is used in the isolation of DNA. To inactivate DNases, the RNase A 
solution should be heated before use for 10 min at 100° C. 
DNase I 
DNase I is a versatile enzyme that nonspecifically cleaves DNA to release 5'-
phosphorylated di-, tri-, and oligonucleotide products. It is a powerful research tool for 
DNA manipulations used in a range of molecular biology applications. Some of its uses 
include: Degradation of contaminating DNA after RNA isolation, "Clean-up" of RNA 
prior to RT-PCR and after in vitro transcription, Identification of protein binding 
sequences on DNA (DNase I footprinting), Prevention of clumping when handling 
cultured cells, and Creation of a fragmented library of DNA sequences for in vitro 
recombination reactions. 
 
2.1.2.5 Antibodies and Fluorescent dyes: 
Antibodies and fluorescent dyes used in the experiments are all commercially available. 
Their parameters were described 
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For Western-blot analysis 
Primary antibodies:  
Anti-HA (monoclonal) mouse (Sigma, Seelze, Germany) 
Anti-human β-Actin (monoclonal) mouse (Abcam, Cambridge, UK) 
Secondary antibody: 
Anti-mouse IgG sheep, biotin conjugated (Bio-Rad, München, Germany)  
For immuno-staining:  
Primary antibody 
Caveolin-1(N-20)sc-894: Anti-Cav-1(polyclonal) rabbit (Santa Cruz Biotechnology).  
Secondary antibodies 
Anti-rabbit IgG donkey, Cy5 conjugated, # 62771 (Dianova) 
Anti-rabbit IgG donkey, Cy-3 conjugated, # 63631 (Dianova) 
Streptavidin Cy-3 conjugated, # 59606(Dianova) 
WGA-633: It is a membrane staining dye. Wheat germ agglutinin W-21404, conjugated 
with Alexa Flur 633 (Molecular Probes, OR, USA). λ-Abs: 632nm and λ-Em: 647nm.   
TO-PRO3: It is a nuclear staining dye (Molecular Probes). λ-Abs: 642nm and λ-Em: 
661nm.   
 
2.1.3 Detection and purification systems (Kits): 
 
Kit Provider 
Nucleobond, Plasmid purification system MACHEREY-NAGEL / Düren, Germany 
QIAEXII gel extraction kit Qiagen / Hilden, Germany 
QIAquick PCR purification kit Qiagen / Hilden, Germany 
BigDye® terminator v3.1 sequencing Applied Biosystems / Darmstadt, Germany 
ECL-kit Amersham / Freiburg, Germany 
AB complex/HRP DakoCytomation  / Hamburg, Germany 
Luciferase reporter assay kit Promega / Mannheim, Germany 
MTT cell proliferation assay Promega / Mannheim, Germany 
CytoTox-ONE membrane integrity assay  Promega / Mannheim, Germany 
 
 
Table 4: Detection and purification systems (Kits) 
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2.4 Methods: 
2.2.1 Cell biology methods: 
2.2.1.1 Culturing human A549, FBPA and SMCPA cells: 
The culturing of the human pulmonary epithelial cell line A549 was performed according 
to the protocol given by the American Type Culture Collection. Human Pulmonary artery 
adventitial fibroblasts (FBPA) and Smooth muscle (SMCPA) cells were isolated and 
cultured as described (74). The cells frozen in DMSO at -70°C (app. 5 x 10
6
 cells) were 
thawed at 37°C and then transferred into a 100 mm dish containing app. 12 ml of A549 
medium. When the cells became confluent, they were treated with 1x trypsin. The 
reaction was stopped by adding 10 ml of medium with 10% FCS (contains trypsin 
inhibitors). For further culturing about 1/3
rd
  of the volume of medium containing cells 
were transferred to a fresh plate and cultured in gas controlled incubators in water vapor 
saturated atmosphere with 1% O2 (v/v) or atmospheric O2 (v/v), 5% CO2 and, 
accordingly, 94% (v/v) or atmospheric N2 at 37°C in normbaric conditions. The cells 
were usually confluent in 3 days. Cells were plated in different sized plates based upon its 
down stream application, as follows: 
 
Slide / Plate size No.of cells Application 
100 mm plate 5 × 106  DNA / RNA isolation  
6 well plate 5 × 105 Fam-DNA / Protein isolation  
24 well plate 1.5 × 105 Transfections/ Reporter assay 
96 well plate 2.5 × 104 Magnetofection/ transfection/Cyto-toxicity 
8 well culture slide 0.5 × 105 Immunostaining 
  
2.2.1.2 Transfections: 
Magnetofection: 
Approximately 2.5 × 104 Cells/ well were added in a 96-well plate and cultured overnight 
at 37
o
C in CO2 incubator. The cells were 85-90% confluent for transfection on the 
following day. 0.2 µg/well DNA was diluted in 25µl Opti-MEM® serum free medium. 
0.5µl/well lipofectamine.2000 was diluted in 25µl Opti-MEM® medium. Mixtures were 
incubated for 5 m at room temperature. The diluted DNA was slowly added to the diluted 
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lipofectamin 2000, mixed and incubated for 15 m at room temperature to facilitate the 
formation of DNA-Lipofectamine (DL) complexes. The CombiMAG/L-200 
magnetofection reagent was vortexed before use. 0.8µl/well CombiMAG/L-200 reagent 
was added to the DL mixture and incubated at room temperature for 15 m. The DL-Mag 
complexes were added to the cells and the 96-well plate was placed over the 96-well 
magnetofactor plate for 15 m for cell-lines and 5-10 m for primary cells. Following the 
incubation over the magnetofactor plate the DL-Mag mixture was replaced by culture 
medium and the cells were incubated at 37
o
C in CO2 incubator overnight.  
 
PEI mediated transfection: 
Stock solution of PEI was prepared by dissolving PEI in water. The resultant stock 
solution (2mg/ml) was then filter sterilized. The following formula was employed to 
calculate the amount of PEI, from the stock solution to be used per µg DNA. The 
calculations are based on the N/P ratio to be employed. N/P ratio was standardized to 4 
after trying N/P ratios ranging from 3 to 6. Higher N/P ratios suggest higher cationic 
behavior and also higher toxicity. 
PEI Formula: 
[(x µg DNA × 43.1µg per µmol) ÷ 330µg per µmol]  × [(y) N: P ratio ÷ 2 (concentration 
of stock solution in mg/ml)] 
Therefore: [(1 × 43.1) ÷330] × [4 ÷2] = 0.26µl from 2mg/ ml stock solution for 1µg 
DNA. 
The cells were plated in the desired culture plates following the specifications mentioned 
in the table in section 2.2.1.1 and cultured overnight at 37
o
C in CO2 incubator to attain 
85-90% confluence for transfection on the following day. DNA was diluted in 150mM 
NaCl (4µg in 125µl/well for 6-well plate, 1µg in 25µl/well for 24-well plate and 0.2µg in 
12.5µl/well for 96-well plate). PEI from the stock solution was diluted in 150mM NaCl 
(1.04µl in 125µl/well for 6-well plate, 0.26µl in 25µl/well for 24-well plate and 0.05µl in 
12.5µl/well for 96-well plate). Mixtures were incubated for 10 m at room temperature. 
The diluted PEI was slowly added to the diluted DNA, mixed and incubated for 10 m at 
room temperature to facilitate the formation of PEI-DNA complexes. Corresponding 
amounts (250µl/well for 6-well plate, 100µl/well for 24-well plate and 50µl/well for 96-
well plate) of the PEI-DNA complexes were added to the cells and an equal volume of 
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OptiMEM was also added to prevent drying of the cells. The cells were incubated at 37
o
C 
in CO2 incubator for 4 h. After 4 h the medium was replaces with culture medium and the 
cells were incubated at 37
o
C in CO2 incubator overnight.   
 
Lipofectamine 2000 mediated transfection: 
The cells were plated in the desired culture plates following the specifications mentioned 
in the table in section 2.2.1.1 and cultured overnight at 37
o
C in CO2 incubator to attain 
85-90% confluence for transfection on the following day. DNA was diluted in Opti-
MEM® serum free medium (4µg in 250µl/well for 6-well plate, 1µg in 50µl/well for 24- 
well plate and 0.2µg in 25µl/well for 96-well plate). Lipofectamine.2000 was diluted in 
Opti-MEM® medium (10µl in 250µl/well for 6-well plate, 2µl in 50µl/well for 24-well 
plate and 0.5µl in 25µl/well for 96-well plate). Mixtures were incubated for 5 m at room 
temperature. The diluted DNA was slowly added to the diluted lipofectamin 2000, mixed 
and incubated for 15 m at room temperature to facilitate the formation of DNA-
Lipofectamine (DL) complexes. Corresponding amounts (500µl/well for 6-well plate, 
100µl/well for 24-well plate and 50µl/well for 96-well plate) of the DL complexes were 
added to the cells and incubated at 37
o
C in CO2 incubator for 4 h. After 4 h the medium 
was replaces with culture medium and the cells were incubated at 37
o
C in CO2 incubator 
overnight.   
 
TRD and TRDL mediated transfection: 
The cells were plated in the desired culture plates following the specifications mentioned 
in the table in section 2.2.1.1 and cultured overnight at 37
o
C in CO2 incubator to attain 
85-90% confluence for transfection on the following day. DNA was mixed with TatRGD 
(2, 4, 6, 12.5, 25µg for dosage curve) and the volume was made up with HBS (50mM 
NaCl and 10mM HEPES). The TatRGD-DNA (TRD) mixture was vortexed and 
incubated at room temperature for 15 m. The resulting mixture was directly used for TRD 
mediated transfection or used for preparation of TatRGD-DNA-Lipofectamine (TRDL) 
complex mixture. Specified amount of lipofectamine was added to the TRD mixture and 
incubated at room temperature for 15 m, in order to form the TRDL complex mixture. 
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Corresponding amounts of the TRD or TRDL mixtures were added to the cells and 
incubated at 37
o
C in CO2 incubator for 4 h. After 4 h the medium was replaces with 
culture medium and the cells were incubated at 37
o
C in CO2 incubator overnight.  
 
Plate/slide (TR-D,TR-D-L/ well) Cell-lines (TR-D-L/ well) Primary cells 
6-well  4µgDNA+48µgTR+HBS(250µl)+10µlLipo 4µgDNA+16µgTR+HBS(250µl)+10µlLipo 
24-well  1µgDNA+12.5µgTR+HBS(75µl)+2µlLipo 1µgDNA+4µgTR+HBS(75µl)+2µlLipo 
96-well  0.2µgDNA+2.5µgTR+HBS(25µl)+0.5µlLipo 0.2µgDNA+0.8µgTR+HBS(25µl)+0.5µlLipo 
8-chamber 0.5µgDNA+6µgTR+HBS(50µl)+1µlLipo 0.5µgDNA+2µgTR+HBS(50µl)+1µlLipo 
 
Table 5: Protocol for TRD and TRDL mediated transfections.  
 
2.2.1.3 Luciferase reporter assay: 
The detection of luciferase activity in the cells transfected with reporter vectors 
containing the firefly gene was performed with the luciferase reporter assay kit 
(Promega). The luciferase assay is based on the enzyme-catalyzed chemiluminescence. 
Luciferin present in the luciferase assay reagent is oxidized by luciferase in the presence 
of ATP, air oxygen and magnesium ions. This reaction produces light with a wavelength 
of 562 nm that can be measured by a luminometer. After washing twice with 1 x PBS, the 
transfected cells were incubated for 15 m in 70 µl of 1x lysis buffer on a shaker. 
Following a cycle of freeze thawing luciferase measurements were performed. For 
measurement of firefly luciferase activity, 20 µl of the lysate were mixed in white and 
flat bottom 96-well plates containing 100 µl luciferase assay reagent, which was freshly 
prepared by mixing substrate and the luciferase assay buffer. The luminescence was 
measured in luminometer for firefly luciferase activity.  
5 x lysis buffer (pH 7.8) Volume Final concentration 
1M Tris 25 ml 125 mM 
200 mM EDTA 10 ml 10 mM 
500 mM DTT 4 ml 10 mM 
85 % Glycerol 115 ml 50 % 
Triton X-100 10 ml 5 % 
H2O to 200 ml  
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Damaged 
cell 
Lactate Pyruvate 
LDH 
NAD+ NADH 
Resazurin 
Resorufin 
Diaphorase 
2.2.1.4 MTT cell proliferation assay: 
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay was first 
described by Mosmann in 1983. It is based on the ability of a mitochondrial 
dehydrogenase enzyme from viable cells to cleave the tetrazolium rings of the pale 
yellow MTT and form dark blue formazan crystals which are largely impermeable to cell 
membranes, thus resulting in their accumulation within healthy cells. The number of 
surviving cells is directly proportional to the level of the formazan product created. The 
color can then be quantified using a colorimetric assay. 
About 5000 cells/well were plated in a 96-well plate. The cells were transfected with 
TRDL vectors. The following morning the medium was replaced by 100µl fresh culture 
medium and the cells were incubated for 2 h at 37
o
C. 10µl of MTT reagent was added in 
each well and incubated for 1-2 h in dark. The color change was carefully monitored. The 
absorbance was measured at 570 nm. A triplicate of untreated cells was taken as blank. 
The average absorbance of blank should range between 0.1-0.2. The sample absorbance 
was calculated as: 
Sample absorbance = Absorbance measured – Average absorbance of blank. 
 
2.2.1.5 Cyto-toxicity assay: 
The cyto-toxicity measurement was performed with the CytoTox-ONE
TM
 homogeneous 
membrane integrity assay. CytoTox-ONE
TM 
is a rapid, fluorescent measure of the release 
of lactate dehydrogenase (LDH) from cells with a damaged membrane. LDH released 
into the culture medium is measured with a 10 m coupled enzymatic assay that results in 
the conversion of resazurin into florescent resorufin. The reagent mix does not damage 
the cells and therefore measurements can be performed in wells containing a mixed 
population of viable and damaged cells. 
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Figure 6: Principle of CytoTox-ONE
TM
 homogeneous membrane integrity assay. Release of 
LDH from damaged cells is measured by supplying lactate, NAD
+
 and resazurin as substrates in 
the presence of diaphorase. Generation of the fluorescent resorufin product is proportional to the 
amount of LDH.  
 
2.5×104 cells/well were plated in a 96-well plate. The cells were incubated with test 
compounds (DNA+OptiMEM, TRD+OptiMEM, TRDL+OptiMEM and DL+OptiMEM) 
for 4 h at 37
o
C. Following this, the test compounds were removed and 100µl culture 
medium was added. Cells were cultured overnight at 37
o
C. The assay plate was removed 
from 37
o
C incubator and equilibrated to 22
o
C for 20 m. 100µl CytoTox reagent was 
added in each well. The plate for incubated at room temperature for 10 m. Following this 
incubation 50µl stop solution was added. The plate was incubated at room temperature on 
a shaker for 10 s and the florescence was measured with an Ex λ - 560nm and Em λ - 
590nm. Triplicate wells with out cells to serve as negative control, in order to determine 
background florescence was employed. Untreated cell control and Maximum LDH 
release controls were also performed in triplicates, with cells untreated with test 
compounds and cells lysed with 2µl lysis solution respectively. 
The average florescence values of the culture medium background were subtracted from 
the experimental values. The percent cyto-toxicity was then calculated employing the 
formula: 
% Cyto-toxicity = 100 × (Experimental – Culture medium background) ÷ (Maximum 
LDH release – Culture medium background)  
 
2.2.1.6 Analysis of DNA uptake: 
A 400bp Fam-CMV fragment was amplified from Pgl3CMV. About 5 × 105 cells/well 
were plated in a 6-well plate and cultured overnight. The cells were transfected in 
duplicates with Fam-CMV employing TRDL and DL vectors. Following this the cells 
were used for DNA isolation.  
 
Fam-CMV  isolation from cell lysate: 
Following transfections, the cells were lysed with 100µl lysis buffer and the lysate was 
PCR column purified. The eluent (100µl) was used for gene scan analysis of Cellular 
DNA.  
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ABI Prism 
310 Genetic Analyzer 
(Gene Scan) 
Cell (C) 
Nucleus (N) 
  
 
Fam-CMV  isolation from Nucleus:  
Following transfections, the cells were subjected to nuclear isolation. The cells were 
washed with PBS for 2 times. The cells were scraped with 500µl PBS and centrifuged at 
400g for 5 m at 4
o
C. The supernatant was discarded and the pellet was re-suspended in 
2000µl buffer I (10mM Tris HCl, 1.5mM MgCl2.6H2O and 10mM KCl, pH-7.8) and 
incubated on ice for 10 m. The cells were homogenized for 10 s at 3000U. The 
homogenate was checked under microscope for nuclear isolation. Confirming nuclear 
release, the homogenate was centrifuged at 4500g for 5 m at 4
o
C. The pellet was re-
suspended in 1000µl buffer II (420mM KCl, 20mM Tris HCl, 1.5mM MgCl2.6H2O and 
20% Glycerol, pH-7.8). The suspension was centrifuged at 10000g for 30 m at 4
o
C. The 
supernatant containing the nuclear extracts were PCR column purified. The eluent 
(100µl) was used for gene scan analysis of nuclear DNA.   
 
Gene Scan analysis:  
Samples for gene scan were prepared by mixing 1µl of each sample (Cell, Nucleus and 
known amounts of Fam-CMV ranging from 0.5ng to 24ng) with 0.5µl of Genescan 500 
TAMRA size standard (PE Applied Biosystems) and 18.5µl of template suppression 
reagent (TSR). The samples were denatured at 99°C for 10 m and cooled on ice for 5 m. 
The samples were run in an ABI prism 310 genetic analyzer, under the conditions: 
Module- GS STR POP4 (1ml) C, Injection seconds- 5, Injection KV- 15, Run KV- 15 
Run °C- 60, Run time- 30 m. The gene scan software was used to size and quantify the 
DNA fragments. 
 
 
 
 
 
 
 
 
Figure 7: Principle of Analysis of DNA uptake. 
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2.2.1.7 Immunostaining and confocal imaging: 
TatRGD and caveolin-1 co-localization: 
About 0.5 × 105 cells/well (A549) were plated in 8-well permanox chamber slides (Lab-
Tek, Naperville, IL, USA) pre-coated with 300 µl fibronectine (20 µg/ml). After 
overnight culturing, A549 cells were transfected with 400 bp DNA fragment (CMV), 
employing TRDL vector system. The cells were fixed at different time points, for 2 h at 
room temperature with PFA (1 ml 4% paraformaldehyde, 0.4 ml 10x PBS and 2.6 ml 
H2O). The cells were washed 3 times with 1x PBS and unspecific binding of the primary 
antibody was blocked for 1 h with 5% BSA and 5% normal goat serum in 1x PBS. 
Following this, the cells were washed and incubated overnight in a humid chamber with 
polyclonal rabbit anti-caveolin-1 primary antibody (1:400) (Santa Cruz, Santa Cruz, 
USA). The cells were washed and incubated for 1 h with Cy5-conjugated donkey anti-
rabbit IgG secondary antibody (1:200) (Dianova, Hamburg, Germany). Then, the cells 
were washed and incubated for 1 h with Cy3 conjugated streptavidin (1:5000) (Dianova, 
Hamburg, Germany) for labeling biotin-TatRGD. The slides were mounted with a 
coverslip and analyzed by laser-scanning confocal fluorescence microscopy for TR and 
caveolin-1 co-localization.    
Cellular internalization of TatRGD: 
The cells were cultured, transfected and fixed as mentioned above. Blocking and 
permeabilization was performed with 10% horse serum, 0.5% Tween 20, 0.1% BSA in 
1x PBS for 1 h. Permeabilization ensures that the secondary reagent (Cy3-conjugated 
streptavidin) enters the cells and labels the biotin-TatRGD which can be analysed by 
confocal microscopy for the cellular internalization of TR.    
Intracellular Localization of DNA:    
Cells (A549 or SMCPA) were transfected with Fam-labeled DNA fragment (Fam-CMV), 
employing TRDL vector system and fixed at different time points with PFA. The cells 
were washed and blocked with 5% BSA, 5% normal goat serum in 1x PBS for 1 h. 
Following this, the cells were washed and incubated overnight in a humid chamber with 
polyclonal rabbit anti-caveolin-1 primary antibody (1:400) (Santa Cruz, Santa Cruz, 
USA). Then, the cells were washed and incubated for 1 h with Cy3-conjugated donkey 
anti-rabbit IgG secondary antibody (1:400) (Dianova, Hamburg, Germany). Afterwards, 
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the cells were incubated sequentially for 10 m with WGA-633 membrane dye (Wheat 
germ agglutinin Alexa Fluor 663-conjugated, Molecular Probes: W-21404, 1:100) and 
TO-PRO-3 nuclear stain (Molecular Probes, 1:800). The cells were mounted with a 
coverslip and analyzed by laser-scanning confocal fluorescence microscopy for the 
intracellular localization of Fam-labeled DNA.     
The following laser lines were employed to detect the corresponding flurophores: Fam 
was detected using the 488nm laser line, Cy-3 was detected using the 543nm laser line 
and Cy-5, WGA-633 and TO-PRO-3 were detected using the 633nm laser line, all with 
appropriate detection bandwidths for each fluorophore. Sequential scanning was 
performed to prevent bleed through into adjacent detection channels. 
           
2.2.2 Molecular biology methods: 
2.2.2.1 Cloning of DNA fragments into plasmids: 
For cloning of the full length RELMβ cDNA we performed RT-PCR using RNA extracts 
from human lung tissue with primers derived from human RELMβ cDNA sequence 
(Acc. No.: AF323084): PHIMF-f and M-HIMF-f. The purified PCR product was ligated 
into pGEM-T-easy plasmid (Promega) and positive clones were sequenced. Inserts from 
pGEM-T-easy plasmid were amplified by PCR for sub-cloning into pCMV-HA 
expression plasmid (Clontech, Paolo Alto, USA) using the following primers: HIMF-
kozak-kpn1 and HIMF-HA-TGA-xho1. The forward primer contained a Kozak sequence 
as an optimized translation start and the reverse primer carried a hemeagglutinin A (HA) 
tag in frame at the C-terminus. Primer sequences are mentioned in the materials section.   
 
2.2.2.2 Polymerase chain reaction: 
In the polymerase chain reaction (PCR), the DNA sequence of interest undergoes 
repeated doubling in an exponential fashion. Two synthetic oligonucleotides (primers) 
complementary to the 3’ end of the target DNA (template) were added at high 
concentrations. The reaction additionally involves the use of four deoxyribonucleotide 
triphosphates (dNTPs) and a heat-stable DNA polymerase. Each cycle consists of three 
reactions that take place under different temperatures. First, the double-stranded DNA is 
denatured (95°C) into its two single strands, which functions as templates for the 
synthesis of new DNA. Second, the reaction is cooled (50-60°C) to allow the annealing 
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of primers to the complementary DNA strands. Third, DNA polymerase extends both 
DNA strands at 72°C starting from the primers.  
 
PCR reaction (per 25 µl) 
Template DNA 10 ng 
Forward primer 10 pmol 
Reverse primer 10 pmol 
40 mM dNTP mix 0.5 µl 
10 x PCR buffer 2.5 µl 
HotstarTaq polymerase 2.5 U 
H2O Made to 25 µl 
 
The PCR was performed in a thermal-cycler programmed as follows: 
 
Activation of HotstarTaq  95
o
C 15 m 
Denaturation  94
o
C 20 s 
Annealing  Table 6 30 s 
Extension  72
o
C Table 6 
Cycles 35 to 40   
Final extension  72
o
C 10 m 
 
After the amplification, PCR products (10 µl) were electrophoretically analyzed in a 1% 
agarose gel with 0.2 µg /100 ml ethidium bromide and purified if required. 
 
DNA fragment Annealing temperature 
 
Extension time 
Fam-CMV / CMV(400bp) 60
o
C 25 s 
Full length HIMF 63.5
o
C 20 s 
HIMF (200bp) 52
o
C 30 s 
HPRT 52
o
C 30 s 
 
Table 6: List of annealing temperatures and extension times for PCR. 
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2.2.2.3 DNA electrophoresis and purification from agarose gel: 
The DNA samples were mixed with loading buffer and loaded onto the 1% agarose gel. 
The electrophoresis was performed for 45-60 m with 5 V/cm. The negatively charged 
DNA migrated from the cathode (-) to the anode (+). To visualize DNA, the gel was 
treated with ethidium bromide (0.5 µg/ml), which intercalated between the bases of DNA 
double strands forming a complex, fluorescent under UV light. The size of DNA 
fragments was determined by a DNA molecular weight standard. 
 
Loading buffer Final concentration 
Bromophenol blue 0.01 g /100 ml (0.01%) 
Glycerol 40 ml /100 ml (40%) 
10 x TAE buffer 10 ml / 100 ml (1x) 
 
The corresponding DNA fragment was excised from the gel and purified with the QIAEX 
II kit (Qiagen). Three volumes of binding and solubilization buffer (QX1) and 10 µl 
QIAEX II solution were added to 1 volume of gel. For effective DNA binding, the 
solution was incubated at 50°C for 10 m with occasional mixing. After centrifugation at 
20,800 g for 30 s, the pellet was washed once with QX1 buffer and once with PE buffer. 
After aspirating the washing buffer, the pellet was completely dried at room temperature 
(for about 15 m). Then, the pellet was re-suspended in 20 µl H2O and incubated for 5 m 
at room temperature. After centrifugation at 20,800 g for 1 m, the supernatant containing 
the DNA fragments was collected into a fresh tube. 
 
2.2.2.4 Direct PCR product purification (column purification): 
The PCR products were purified with the Qiaquick PCR purification kit (Qiagen). 
Binding buffer (BP) was added to PCR solution at the ratio of 5:1 v/v, respectively. The 
solution was loaded onto the Qiaquick column to which the DNA binds. After 
centrifugation at 20,800 g for 30 s, the column was washed with washing buffer and 
completely dried by centrifuging at 20,800 g for 1 m. Then, the fragment was eluted in 
50µl H2O by centrifugation at 20,800 g for 1 m into a fresh tube. 
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2.2.2.5 Restriction digestion: 
The DNA fragments (Plasmid or PCR products) were restriction digested using the 
following protocol. The mixtures were incubated at temperatures for maximum activity 
of the specific enzymes. 
Total reaction volume (per 10 µl) 
Plasmid / PCR product 3 µg / 8 µl 
Enzyme 1µl 
10 x buffer 1µl 
 
2.2.2.6 Ligation: 
The purified DNA fragments were ligated into the linearized plasmids by T4 ligase. The 
ligation reaction was incubated overnight at 16°C and then transformed in the competent 
E.Coli cells. 
 
Total reaction volume (per 10 µl) 
DNA fragment 100 ng 
Linearized plasmid 50 ng 
10 x ligase buffer 1µl 
T4 DNA ligase 1µl 
H2O Up to 10 µl 
 
2.2.2.7 Preparation of competent E.coli : 
A single bacterial colony from the E.Coli TOP10 glycerol culture was cultured in 5 ml 
LB medium at 37°C overnight. Following day, the bacterial suspension was diluted into 
500 ml LB medium and cultured till the OD at 550 nm became 0.3-0.4 (about 3-6 h). The 
suspension was centrifuged at 4°C, 5000 g for 15 m. The pellet was re-suspended in 100 
ml (1/5
th
 vol) ice-cold 50mM CaCl2 and kept on ice for 5 m. The cells were again 
centrifuged at 4°C, 5000 g for 15 m. The pellet was re-suspended in 25 ml (1/20
th
 vol). 
The cells were again centrifuged at 4°C, 5000 g for 15 m and pellet was re-suspended in 
5 ml of 50 mM CaCl2 in 20% glycerol. Suspension was divided in 50 µl aliquots and 
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stored at -70°C. The competence of the bacterial cells was checked by the transformation 
of an ampicillin resistant plasmid. 
 
Luria Bertani medium (LB) Final concentration 
Tryptone 10 g/l 
Yeast extract 5 g/l 
NaCl 10 g/l 
pH 7.3 
 
2.2.2.8 Transformation of E.coli: 
The transformation of E.coli was performed by heat shock method. The ligation mixture 
or the plasmid DNA was gently mixed with one aliquot of the competent cells and 
incubated at 4°C for 30 m. Then the mixture was heated to 42°C for 2 min and cooling on 
ice immediately. Thereafter, the bacterial cells were cultured in 200 µl SOC medium 
without antibiotics at 37°C for 1h. An aliquot of 100 µl was spread over an ampicillin 
containing agar dish and incubated overnight at 37°C. 
 
SOC medium Final concentration 
Tryptone 2 % 
Yeast extract 0.5 % 
NaCl 10 mM 
KCl 2.5 mM 
MgCl2 10 mM 
MgSO4 10 mM 
Glucose 20 mM 
pH  7.3 
 
Ampicillin agar dishes: 
For preparing the agar plates, 500 ml LB medium containing 7.5g bactoagar was 
autoclaved. After cooling to 50°C, 500 µl ampicillin stock solution (final concentration 
10% w/v) was added, mixed and 20 ml of the solution was poured into each sterile 
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culture dish. The dishes were left for solidifying at room temperature overnight and then 
stored at 4°C in the dark. 
Ampicillin stock solution: 0.1 g/ml 
Colony PCR from bacterial culture: 
The bacterial colonies transformed with a ligation mixture or with a plasmid, were picked 
and cultured in 5 ml LB medium with ampicillin (100µg/ml) at 37°C overnight. 10 µl of 
each bacterial culture was re-suspended in 90 µl of H2O, heated at 95
o
C for 10 m and 
cooled on ice. 1 µl of this suspension was used as template in setting the 25 µl PCR 
reaction using the primers specific for the fragment in question.  
 
2.2.2.9 Isolation of plasmid DNA: 
The maxi-preparation of plasmid DNA was performed with Nucleobond AX500 Maxi-
prep Kit according to manufacturer’s descriptions. The transformed E.Coli TOP10 cells 
were cultured in 200 ml LB medium to a density of about 109 per ml (OD at 600 nm of 
1-1.5). The cells were pelleted by centrifugation at 4°C, 5860 g (6000 rpm, GSA rotor) 
for 30 m. The pellet was re-suspended in 10 ml of buffer S1, which contained 100 µg/ml 
of RNase. Then 10 ml of buffer S2 (with NaOH and SDS for bacterial lysis) was added 
and mixed gently 4-6 times (the mixture was not vortexed to avoid shearing of genomic 
DNA). After 5 m incubation at RT (longer incubation could lead to irreversible 
denaturation of plasmid DNA), 10 ml of buffer E3 was added to neutralize the solution. 
The solution was filtered using the paper filters provided in the kit. The filtrate was 
carefully applied to the column, which was equilibrated with 6 ml of buffer N2. When the 
lysate has been completely run by gravity flow, the column was washed twice with 18 ml 
of buffer N3 to remove single stranded DNA, RNA and all other impurities such as 
proteins, metabolites, polysaccharides and NTPs. Afterwards, the double stranded 
plasmid DNA was eluted with 15 ml of buffer N5 and precipitated by adding 10.5 ml of 
isopropanol. Plasmid DNA was pelleted by centrifugation at 4°C, 27000 g (5000 rpm, 
SS34 rotor) for 30 m. The DNA pellet was washed with 70% ethanol, to remove salts, 
air-dried for 30 m and dissolved in 500 µl H2O. 
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To determine the DNA concentration and the presence of protein in the probes, the OD at 
260 nm (DNA) and 280 nm (protein) was measured. The prepared plasmids were 
checked by restriction analysis as described above. 
Buffers used in maxi preparation: 
Buffer S1 Final concentration 
Tris-HCl 50 mM 
EDTA 10 mM 
RNase A 100 mg/ml 
pH  8.0 
S1 with Rnase A was stored at 4°C 
Buffer S2 Final concentration 
NaOH 200 mM 
SDS 1 % 
 
Buffer S3 Final concentration 
Potassium acetate pH 5.1  2.8 M 
 
Buffer N2 Final concentration 
Tris 100 mM 
Ethanol 15 % 
KCl 900 mM 
Triton X-100 0.15 % 
pH (adjusted with H3PO4) 6.3 
 
Buffer N3 Final concentration 
Tris 100 mM 
Ethanol 15 % 
KCl 1.15 M 
pH (adjusted with H3PO4) 6.3 
Buffer N5 Final concentration 
Tris 100 mM 
Ethanol 15 % 
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KCl 1.0 M 
pH (adjusted with H3PO4) 8.5 
 
2.2.1.10 Sequencing of plasmids: 
The sequencing was performed by a “Big-dye terminator cycle sequencing” method 
following the manufacturer’s protocol (Perkin Elmer). In this method, the premix 
solution contains four dideoxynucleotides (ddNTP, each labeled with a different 
fluorescent dye), unlabeled deoxynucleotides (dNTP) and a temperature resistant DNA 
polymerase. The template plasmid and the gene specific primer (forward or reverse) were 
added to the reaction mixture. During the PCR reaction, the synthesized single strand 
DNA would be stopped randomly with the incorporation of ddNTP. Thus, DNA 
fragments of different size were labeled at their 3´-ends with base specific fluorescent 
dyes, which could be analyzed with the DNA sequencer (ABI, model 310 Genetic 
Analyzer) 
 
Sequencing reaction Volume Final concentration 
Plasmid x µl  1µg/probe 
Primer (2.5 pmol/µl) 2 µl 5 pmol/probe 
Premix 2 µl  
H2O to 10 µl  
 
The sequence reaction was performed under following conditions: denaturation at 96°C 
for 10 s, primer annealing at 50°C for 5 s, extension at 60°C for 4 m. After the 
sequencing reaction the solution was cooled at 4°C and purified as follows: 
10 µl 3 M NaAc, pH 5.2, 80 µl H2O and 250 µl 95% ethanol (RT) was added to the 
sequencing mixture and centrifuged for 20 m at 15,800 g (14,000 rpm, table centrifuge). 
The pellet was washed with 250 µl of 70% ethanol, centrifuged for 10 m, air-dried and 
re-suspended in 20 µl of Template Suppression Reagent (TSR). Then, the probe was 
loaded on the capillary sequencer using the performance-optimized polymer 6 (POP6). 
The fluorescent signal was identified by the detector system of the DNA sequencer and 
quantified. 
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2.2.1.11 RNA isolation from cultured cells: 
The RNA was extracted from cells using guanidine thiocyanate-acid phenol (RNAzol-B, 
WAK-Chemie, Germany). RNAzol-B is a complete and ready-to-use reagent for isolation 
of total RNA from samples of human, animal, plant, bacterial and viral origin. A 
biological sample was lysed in RNAzol-B and the lysate was separated into aqueous and 
organic phase by the addition of chloroform. The subsequent centrifugation efficiently 
removes DNA and proteins from the aqueous phase containing RNA. The non-degraded, 
pure RNA is obtained from the aqueous phase by the isopropanol precipitation. The RNA 
pellet was washing with ethanol and solubilized in an appropriate solution. Cultured cells 
(3 x 10
5
 cells in 6 well culture dishes) were washed with 1 x PBS, and scraped in 400 µl 
RNAzol-B buffer with a disposable cell scraper. The cell lysate was homogenized by 
pipetting up and down, and then transferred into a 2 ml Eppendorf cup. Thereafter, 80 µl 
of chloroform was added with gentle mixing. The solution was incubated on ice for 15 m 
and centrifuged at 10000 g, 4°C for 20 m. The RNA-containing upper phase was 
collected in a new 2 ml Eppendorf cup. The RNA was precipitated by addition of 0.2 ml 
isopropanol and centrifuged at 10,000 g, 4°C for 10 m, the RNA pellet was washed once 
with 200 µl 70% ethanol. The purified RNA was centrifuged again for 10 m at 10,000.g 
and dried in an air at room temperature for 10 m. Finally, the pellet was dissolved in 30 
µl H2O. After measuring the RNA concentration the samples were stored at -70°C. 
To determine the concentration and purity of the RNA, the extinction at 260 nm and 280 
nm was measured. An OD of 1 at 260 nm corresponds to 40 µg RNA/ml. The ratio of the 
OD at 260 nm and at 280 nm is a measure of RNA purity. In a protein-free solution the 
ratio OD260/OD280 is 2. Due to protein contaminations this coefficient is usually lower. 
In our experiments it was between 1.6 and 2. 
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2.2.1.12 Preparation of cDNA from RNA probes: 
For the preparation of cDNA, 1µg RNA per sample was used. RNA was copied to cDNA 
using reverse transcriptase (MMLV-RT) (Invitrogen, Carlsbad, USA) with p(dT)15 
primers. For the negative controls, MMLV-RT was omitted. 
RNA (1 µg /10 µl) was denatured at 65oC for 5 m followed by rapid cooling and addition 
of 10 µl master mix; containing the following: 
5x first strand buffer  4 µl 
0.1 M DTT 2 µl 
10mM dNTP mix 1 µl 
p(dT)15 primer 1 µl 
RNase inhibitor 1 µl 
MMLV-RT (200U/1 µl) 1 µl 
 
 
The denatured RNA mixed with master solution was then subjected for cDNA synthesis 
by incubating at 39
o
C for 1 h followed by inactivation of enzymes at 96
0
C for 2 m. 
(DNase treatment prior to RNA denaturation was performed to some samples where 
genomic DNA contamination was encountered. DNase was added at a concentration of 
10 units/µg RNA and incubated at 37
0
C for 30 m. Following this RNA denaturation was 
performed at 65
0
C. At this temperature the DNase is also deactivated).  
 
2.2.1.13 Protin preparation and Western blot analysis: 
Total protein isolation from the cultured cells: 
The cultured cells were washed with ice-cold 1 x PBS and lysed using 1x Lamelli buffer 
(NuPAGE LDS sample buffer- 4x) was diluted to 1x with 2% mercaptoethanol. The 
mixture was incubated at 95°C for 5 m before adding to the cells). 
PolyAcrylamide Gel Electrophoresis of protein (SDS-PAGE):  
In SDS-PAGE the denatured polypeptides bind to SDS and become negatively charged. 
The amount of SDS bound is always proportional to the molecular weight of the 
polypeptide and is independent of its sequence. Therefore, SDS-polypeptide complexes 
migrate through polyacrylamide gels in accordance with the size of the polypeptide. By 
using markers of known molecular weight, it is therefore possible to estimate the 
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molecular weight of the polypeptide chains. Protein sample from cell lysate and 
supernatant was denatured by heating to 95°C for 5 min in 1 x loading buffer, and then 
cooled on ice immediately. The samples were collected by brief centrifugation and then 
loaded on ready to use Novex 16% Tricine gel. The electrophoresis was performed at 
constant volt at 200 V and the gel was run till the bromophenol blue reached the bottom 
of the resolving gel (for about 1 h). The gel was then used for Western-blot analysis 
 
Electro blotting of immobilized proteins: 
The separated proteins on the SDS-polyacrylamide gel were electrically transferred to a 
polyvinylidene fluoride (PVDF) membrane by electro blotting. The PVDF membrane 
was activated by methanol before use. The transfer equipment was prepared in the 
following way: two layers of 3mm Whatmann filter paper washed with transfer buffer 
followed by activated PVDF membrane washed with transfer buffer were placed onto the 
electro blotting chamber. On the PVDF membrane, the gel and the other two layers of 
filter paper washed with transfer buffer were placed. The cathode and anode from the 
power supply were connected with the electro-blotting chamber. Electro blotting was 
performed at constant current (2mA / cm
2
) for approximately 90 min.  
 
Transfer Buffer (pH = 8.3) Final concentration 
Tris 25 mM 
Glycine 192 mM 
Methanol 20 % 
SDS 0.01 % 
 
Immunological detection of immobilized proteins: 
The membrane was blocked with 0.25% gelatin in 1 x NET buffer at room temperature 
for 1h followed by incubation with primary antibody at 4°C overnight. After washing 
with 1 x NET for three times (10 m each), the membrane was incubated with the 
respective secondary antibody at room temperature for 2 h followed by three times 
washing with 1 x NET buffer. Membrane was then incubated with biotin-streptavidin-
horseradish peroxidase complex for 1 h followed by three times washing with 1 x NET 
buffer. The protein bands were detected by ECL (Enhanced Chemi-luminescence) 
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GMLGISYGRKKRRQRRRPPQT GGCRGDMFGC Biotin 
Tat RGD 
treatment, followed by exposure of the membrane in fluorChem 8900 chemi-
luminescence imager. 
 
10 x NET buffer Final concentration 
NaCl 1.5 mM 
EDTA (pH = 8.0) 50 mM 
Tris 500 mM 
Triton X-100 0.5 % 
 
2.2.1.14 Conjugate peptide TatRGD synthesis: 
The biotinylated TatRGD (TR) peptide consisting of the truncated Tat domain at the N-
terminus and the domain with an RGD motif at the C- terminus had the following 
sequence: (Biotin–GMLGISYGRKKRRQRRRPPQT GGCRGDMFGC). This peptide 
was synthesized (Peptide- Synthesizer 432A, Applied Biosystems Fmoc-chemistry) and 
labeled at the N-terminus with biotin. After deprotection it was purified by HPLC. The 
two cysteine residues were oxidized by air-oxygen and a second HPLC purification was 
performed.  
 
 
 
 
 
Figure 8: TatRGD conjugated peptide. Biotinylated TatRGD peptide, contains 21mer Tat (dark 
gray) and 10mer RGD (light gray) sequence. The peptide has in total 7 Arginine residues (white), 
which contribute to the net positive charge of the peptide. 
 
2.2.1.15 Particle size measurements: 
Particle size measurements were performed using the Zeta sizer, which is based on the 
principle of light scattering. DNA (1µg) was mixed with different concentrations of 
TatRGD (2, 4, 6, 12.5, 25µg) in HBS (pH-7.4), in order to obtain TRD mixture. The 
mixtures were incubated for 15 m and measured for particle size using a zeta sizer. TRDL 
complexes were obtained by adding 2µl lipofectamine to the TRD mixture and 
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incubating for 15 m at room temperature. The TRDL mixtures were then measured for 
particle size using zeta sizer. 
 
2.2.1.16 Sephadex Column packing and separation: 
Sephadex G-100 (Pharmacia Biotech, Uppsala, Sweden) was employed for separation. 
To pre-swell the gel, 250 ml ultrafiltered water was added to 3g Sephadex G-100. The gel 
was autoclaved and incubated overnight at room temperature. When the pre-swollen gel 
settled at the bottom of the bottle, the slurry supernatant was decanted to remove the gel 
fines. Additional 200 ml ultrafiltered water was added to prevent gel drying. 
 
Column packing: 
23 cm Glass chromatographic columns (Glass pasture pipettes, VWR International), with 
10cm packing volume, were employed. The bottom of the column was blocked with 
cotton wool and clamped vertically with the separation nozzle facing down. Before 
packing the column with Sephadex G-100, 500µl HBS was added to the column in order 
to ensure free flowing. The pre-swollen gel was mixed to obtain homogeneous slurry. 
The gel slurry was then added to the column avoiding any air bubble formation. All 
columns were packed to 5 cm height. Equilibration of the columns was performed with 
HBS buffer. 
 
Sample separation: 
Following the equilibration of the column with HBS buffer, 75µl of the sample (1µg 
DNA + 2, 4, 6, 12.5 and 25 µg TR for each sample. The volume was made to 75µl with 
HBS and samples incubated for 15 m) was loaded into the column. Additional 500µl 
HBS was added and the eluents were collected in 10 batches with 6 drops in each batch. 
Control samples without column elution, were prepared with 1µg DNA + 2, 4, 6, 12.5 
and 25 µg TR for each sample. The volume was made to 75µl with HBS and samples 
incubated for 15 m. The eluents collected from the sephadex columns and the 
corresponding control samples, were vacuum dried and re-suspended with 10µl 20x SSC 
(3M Sodium Chloride and 0.3M Sodium Citrate, pH- 7.0) for dot-blot analysis. 
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2.2.1.17 Dot-blot analysis: 
The samples obtained from the Sephadex column separation, were dotted on a nylon 
membrane and the membrane was baked at 60°C for 5 m. The 1x blocking buffer was 
prepared by diluting the 10x stock solution (Blocking reagent for nucleic acid 
hybridization and detection (Roche), was dissolved in maleic acid buffer to a final 
concentration of 10% w/v with heating and shaking. The 10x stock solution was 
autoclaved and stored at 4
o 
C) with maleic acid buffer (100mM maleic acid and 150mM 
NaCl, Ph-7.5). The membrane was blocked with 1x blocking buffer for 1 h. The 
membrane was then washed for 3 times with 50mM Tris and 0.1% Tween 20, pH – 7.4. 
The membrane was then incubated with avidin peroxidase (1:5000) for 1 h, followed by 
3x washing. The membrane was developed with Diamino benzydene (DAB) substrate 
(4mg DAB, 4.5ml 50mM Tris, 0.5ml NiCl2, 5µl H2O2). Quantification of the dots was 
performed by employing densitometric software (fluorChem 8900 chemi-luminescence 
imager). 
In order to obtain the total signal intensity caused by different concentrations of TR the 
standard curve was plotted, by dotting TRD (containing 1µg DNA + 2, 4, 6, 12.5 or 25µg 
TR) directly (with out column separation) on the membrane and backing at 60
o
C. The 
dots were developed and quantified as mentioned above and used to plot the standard 
curve.  
 
Note: Since TR and not the plasmid DNA, is biotin conjugated the color development 
with avidin peroxidase incubation and subsequent development with DAB, is due to TR. 
While TR does not bind to nylon membrane by it self (observed by dotting TR alone on 
the membrane, gave no colored dots). It requires binding with DNA for successful 
colored dotting on the blot. Backing however facilitates residual amounts of TR un-
complexed with DNA also to bind to the membrane. Hence the standard curve was 
plotted to obtain the total signal intensity caused by different concentrations of TR.  
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2.3 Security Measures: 
All the operations with genetically modified organisms and plasmid DNA were 
performed according to the ‘‘Gentechnikgesetz of 1990’’ and to the rules prescribed by 
the ‘‘Gentechnik-Sicherheitsverordnung of 1990’’. Materials contaminated with bacterial 
cells were autoclaved. The chemicals like formaldehyde, DEPC, phenol and ethidium 
bromide are carcinogenic and were carefully managed and disposed.  
 
 
 
 
Chapter 3                                       Results 
 51 
3. Results: 
3.1 Synthetic peptide TatRGD mediated gene transfer in lung cells: 
3.1.1 TatRGD and DNA Binding Analysis: 
We performed binding experiments between TatRGD (TR) and DNA, to determine an 
appropriate concentration ratio of TR and DNA. Firstly, the standard curve was obtained 
by dotting biotin-TRD (containing 1µg DNA mixed with 2, 4, 6, 12.5 or 25µg TR) 
directly (with out column separation) on the membrane and backing at 60
o
C. The dots 
were developed, quantified and used to obtain the standard curve. The intensity of the 
dots obtained were directly proportional to the amount of TR employed (figure 9-A).  
TatRGD-DNA (TRD) complexes were prepared by mixing 1µg DNA with corresponding 
concentrations (2, 4, 6, 12.5, 25µg) of biotin-TR in HBS at physiological pH. These TRD 
mixtures were passed through Sephadex G-100 columns and eluted in 10 fractions 
containing 6 drops each. When biotin-TR alone was passed through the column no dots 
were found on the blotting membrane until 12 fractions (no color appeared on the blots). 
Hence the TRD complexes were eluted in 10 fractions for each sample. The eluents from 
Sephadex G-100 seperation were dot-blotted and quantified as mentioned in the methods 
section. When TRD mixtures were passed through the Sephadex G-100 columns, only 
stable TRD complexes formed were assumed to be eluted in the first 12 fractions. The 
results obtained were in correspondence with this. Colored dots were seen only in the 5
th
 
and 6
th
 fractions of elution (figure 9-B). By fitting these values in the standard curve the 
approximate amounts of TR bound per µg DNA was obtained. 
 The binding curve was then plotted with the input amount of TR on the x-coordinate and 
the amount of TR bound to 1µg DNA on the y-coordinate (figure 9-C). Figure 9-B and C 
suggests that, a minimum of 4µg TR is required per µg DNA to obtain TRD complexes. 
Binding saturated at approximately 12 µg TR per µg DNA. 
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Figure 9: TRD binding analysis. Dot blots obtained by direct application of TRD complexes 
were used for obtaining the standard curve (A). Dot blots were obtained by dotting eluents from 
column separation (B). Binding curve suggested the amount of TR bound /µg DNA (C). 
      
 
3.1.2 Particle size measurement: 
Since the size of the particle is one of the important criterions for its cellular 
internalization, particle size measurements were performed for TRD and TRDL 
complexes. When TatRGD and DNA were alone measured, the average diameter was 
beyond the range of the instrument (i.e.) >6µm. But, when TatRGD was mixed with 
DNA, the average diameter of the TRD complexes reduced ranging between 1µm and 
2.5µm. TRD complexes with lower TR concentrations formed particles with smaller 
diameters. Further reduction in the average diameter was observed when lipofectamine 
was added to the TRD mixtures. This suggests that, addition of lipofectamine to TRD, 
results in further compaction of the particles which aids in better internalization. 
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Figure 10: Particle size measurements. Measurement of particle sizes of different amount of 
TR added to DNA (TRD) or different amounts of TR added to DNA complexed with 
Lipofectamin (TRDL). Z. Avg represents the average size.  
   
 
3.1.3 Dose response: 
To investigate the applicability of TatRGD as a transfection agent, the effect of different 
TR amounts per µg DNA on transfection efficiency was studied employing luciferase 
reporter gene.  
In case of A549 cells, significant transfection efficiencies with TRD vectors were 
observed (figure11-A). Expression levels were observed to be substantially higher when 
cells were transfected with TRDL vectors obtained by addition of Lipofectamine to TRD 
mixtures (figure11-B).  
In primary pulmonary artery cells, such as adventitial fibroblasts (FBPA) (figure11-C) and 
smooth muscle cells (SMCPA) (figure11-D), TR alone was not sufficient for DNA 
transfection. However, TRDL vectors significantly improved the luciferase expression 
levels over that of Lipofectamine standards. 
Careful observation of the cells before adding lysis buffer revealed lowered cell viability 
at higher concentrations of TR. This may be attributed to the decline in transfection 
efficiency at higher concentrations of TR in A549 cell-line (25µg) as well as FBPA and 
SMCPA primary cells (4µg). 
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Figure 11: Dose response in A549, FBPA and SMCPA cells. Dose response in A549 cells 
towards TRD (A) and TRDL (B) mediated transfections. Dose response in FBPA (C) and SMCPA 
(D) primary cells towards TRDL mediated transfections. 
   
 
3.1.4 Cyto-toxicity assay:  
To derive an optimal TR concentration for transfection with minimally compromising 
cell viability, the cytotoxicitiy associated with different concentrations of TRD and 
TRDL vectors on the A549 cell-line (figure12-A) and FBPA primary cells (figure12-B) 
was assessed. Increasing amounts of TR enhanced the toxicity. Also, the toxicity was 
enhanced by the addition of Lipofectamine by at least 5% when delivering TRDL into the 
cells. Further more, the cellular response to test compounds followed the order: TRDL > 
DL > TRD > D.  
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Figure 12: Cyto-toxicity assay. Measurement of cytotoxicity in A549 cells (A) and FBPA cells 
(B) treated by different concentrations of TR in the presence of a given amount (1µg) of DNA 
(TRD) or of DNA and Lipofectamin (TRDL).  
 
3.1.5 Improvement in transfection efficiency with TRDL vector systems: 
Considering the curves of Figures 11 and 12 the optimal concentrations of TR (per 
microgram of DNA) to be employed in all further analysis using TRDL vectors was 
estimated as 12.5µg for A549 and 4 µg for FBPA and SMCPA.  
The analysis of DNA transfection by TRD, LD, and TRDL was shown in comparison, by 
measuring the reporter gene luciferase expression in cellular lysate and by counting the 
GFP positive cells by fluorescence microscopy (figure13).  
In A549 cells the transfection efficiencies of TRDL complexes showed 5-fold 
improvement over the standard lipofectamine (DL) aided transfection. Further, the 
addition of lipofectamine improved the transfection efficiency of TRD complexes by 
approximately 30-fold.  
In FBPA and SMCPA cells the transfection efficiencies of TRDL vectors showed 3 and 2-
fold improvement respectively, over that of DL. 
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Figure 13: TRDL improved transfection efficiency. Summary on transgene expression levels 
employing different mixtures of TRD, DL and TRDL as measured by luciferase reporter gene 
expression in case of pgl3CMV transfection (RLU: relative light units) (left) or by counting 
number of fluorescent stained cells in case of pEGFP-N2 (right) transfection in A549 (A), FBPA 
(B) and SMCPA (C) cells. 
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3.1.6 Analysis of DNA uptake: 
For characterization of the facilitated gene transfer, the cellular uptake of fluorescent 
Fam labeled DNA fragments was studied in A549 and FBPA cells transfected with either 
DL or TRDL. A 409bp fluorescent DNA fragment (Fam-CMV) amplified from 
pgl3CMV (figure 14-A) was employed for this purpose. The quantity and integrity of the 
409bp fragment was analyzed by capillary gel electrophoresis (Gene Scan) (figure 14-B). 
Recovering the DNA fragment from the cellular and nuclear compartments of the cells 
transfected with TRDL and DL vectors exhibited that, TRDL significantly enhanced 
cellular DNA uptake over that of DL vector system and that the effect is more 
pronounced in A549 cells (figure 14-C) than in FB (figure 14-D). 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Analysis of DNA uptake. Fam-CMV is a 409bp fluorescent DNA fragment 
amplified from pgl3CMV (A) [Lane 1: PCR amplified product from plasmid. The 409bp 
fragment was excised and gel eluted. Lane 2: PCR product after gel elution. M: Marker]. The 
quality and integrity of the DNA fragment can be observed from the electropherogram (B). 
Analysis of DNA uptake revealed higher localization of the fluorescent DNA fragment in the 
cellular and nuclear compartments with TRDL mediated transfection over that of DL mediated 
transfection, in both A549 cell-line (C) and FBPA primary cells (D). [C: cellular and N: nuclear 
compartments] 
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3.1.7 TRDL transfection efficiency over commercial standards: 
Comparison of TRDL mediated transfection with commercially available magnetic beads 
(CombiMag, Chemicell), Cationic polymer (25 kDa PEI, Aldrich) and cationic lipid 
(Lipofectamine 2000, Invitrogen) revealed approximately 3.5, 90, 5-fold improvement 
over CombiMAG, PEI and Lipofectamine 2000 respectively in A549 cells (figure 15-A), 
1.3, 23, 3-fold respectively in FBPA cells (figure 15-B) and 4, 65, 2-fold respectively in 
SMCPA cells (figure 15-C). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 15: TRDL transfection efficiency over commercial standards. TRDL mediated 
transfection was observed to be superior over other commercially available transfection agents in 
A549 cell-line (A) and FBPA (B), SMCPA (C) primary cells. 
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3.1.8 Immunostaining and confocal imaging: 
 
Caveoli mediated internalization of TRDL complexes: 
 
To explore if the mode of internalization exploited by TRDL vector system is linked with 
caveoli-mediated endocytosis we performed laser scanning fluorescent confocal 
microscopic analysis by immune-staining the cells for caveolin-1 (blue) and TR (red). 
The cells were not permeabilized to detect only the TR localized at the membrane. In our 
experiments we found a significant co-localization between caveolin and TR (pink 
colour). The fluorescent signal of TR was visualized at different time points during 
transfection (Figure 16-A: a to c). The signal was initially localized on the cell 
membrane. However, a time dependant clearance of the signal from the cell membrane 
was observed. 
  
In order to show the time dependent cellular internalization of TR, the cells were 
permeabilized and then stained with streptavidin-Cy3 (red) for intracellular tracking of 
TR. We observed a strong Cy3 signal at the cell periphery at 2 h, which gradually moved 
into the cell cytoplasm after longer incubations resulting in a strong cytoplasmic signal 
after 15 h (Figure 16-A: d to f).  
 
In order to examine if DNA internalization corresponded with that of TR, the cells were 
transfected with a 400 bp Fam-labeled DNA fragment using TR and the transfection 
process was examined by visualizing the uptake of Fam-labeled DNA into the cells at 
different time points (Figure 16-B: a to c). We employed Cy3-tagged secondary antibody 
for caveolin-1 in these experiments and labeled the cytoplasmic and nuclear 
compartments of the cell with WGA-633 and TO-PRO-3 for the membrane and nucleus, 
respectively. We observed a strong correlation in time between the cellular internalization 
of DNA and that of TR.  
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Figure 16: TatRGD co-localization with Cav-1 and its cellular internalization (A). A549 
cells were transfected with 400bp DNA fragment using TRDL vectors, fixed at 2 h (A-a), 4 h (A-
b) and 15 h (A-c) time points and immuno-stained with anti-Cav-1-Cy-5 (blue) and streptavidin-
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Cy-3 (red) for caveolins and biotin-TR respectively. We observed co-localization (merge) of TR 
with Cav-1 (pink) and a time dependant clearance of TR from the cell membrane. When cells 
were permeabilized and stained with streptavidin-Cy-3, we observed a time dependant 
internalization of TR (red) into the cytoplasmic compartment of the cells (A-d to f). TatRGD 
mediated DNA internalization in cellular compartments (B). A549 cells were transfected with 
400bp Fam labeled DNA fragment using TRDL vectors, fixed at 2 h (B-a), 4 h (B-b) and 15 h (B-
c) time points and immuno-stained with anti-Cav-1-Cy-3 (red) for Caveolins. In order to 
distinguish the cellular compartments, the cells were stained with WGA-633 (blue) and TO-PRO-
3 (blue) for cell membrane and nucleus respectively. We observed a time dependant cellular 
internalization of Fam labeled DNA, which corresponded with the internalization patterns of TR 
in permeabilized cells. 
 
 Cellular internalization of TRDL in relation with caveolin expression: 
Pulmonary cell-line (A549) and primary cells (SMCPA) were transfected with Fam 
labeled DNA fragment and the cells were immuno-stained for Cav-1 (with secondary 
antibody conjugated with Cy-3). We observed a strong correlation between the DNA 
(Fam) internalization and the expression pattern of caveolins in these cell types. A549 
cell-line exhibited strong membrane caveolin staining and also higher Fam internalization 
(figure 17-A). While SMCPA primary cells exhibited weak membrane caveolin staining 
and also lower Fam internalization (figure 17-B) 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A549 cell-line 
SMCPA primary cells 
A 
B 
Chapter 3                                       Results 
 62 
Figure 17: Cellular internalization of TRDL in relation with caveolin expression. 
A549 cell-line SMCPA primary cells were transfected with Fam-DNA (green) employing TRDL 
vectors and stained with WGA-633 (blue), TO-PRO-3 (blue), anti-Cav-1-Cy-3 (red) for cell-
membrane, nucleus and caveolins respectively. We observed that, the caveolin staining at the cell 
membrane was strong in A549 cells (A: above) and relatively weak in SMCPA cells (B: above). 
We observed that, Fam-DNA localization in the cellular and nuclear compartments was strong in 
A549 cells (A: below) and relatively weak in SMCPA cells (B: below). 
 
 
3.1.9 Functional assay:  
Prevention of Caveoli formation by cholesterol depletion: 
To demonstrate further that internalization of TRDL complexes exploit caveolar 
endocytic system, we tested the effect of drugs on TRDL mediated internalization. 
Methyl-β-cyclodextrin specifically disrupts the formation of caveoli with out interfering 
with other modes of endocytosis (75). Cells were pretreated with 1% methyl-β-
cyclodextrin for 30 m and transfected with TRDL complexes. Prevention of caveoli 
formation drastically decreased the transfection efficiency with TRDL vector system 
while that with the standard vector system however remained unaffected (figure 18), 
suggesting the role of caveoli in the cellular internalization of TRDL complexes. 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 18: Prevention of Caveoli formation by cholesterol depletion. A549 Cells were pre-
treated with 1% MBC for 30 m and transfected with TRDL and DL vector systems and the 
luciferase reporter gene expression was measured. Cells untreated with MBC were taken as 
controls for both TRDL and DL transfections. 
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3.2 Application: 
3.2.1 Homology alignment on human RELMβ and mouse HIMF:    
We initially isolated a full-length cDNA of RELMβ from human lung tissue RNA by RT-
PCR strategy. The nucleic acid sequence (Submitted to EMBL, Acc. No: AM050721) 
differed at positions 59 and 97 after start of translation from a published sequence 
(Acc.No. AF323084), resulting in two amino-acid exchanges (proline to leucine and 
lysine to glutamine). The alignments and homologies of human RELMβ with mouse 
HIMF on cDNA (Figure 19-A) and amino acid (Figure 19-B) sequence levels are shown 
below. Sequence analysis exhibited 69.9% similarity in nucleic acid sequence and 50.4% 
similarity in amino acid sequence between the human RELMβ and mouse HIMF.  
 
 
 
A 
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Figure 19: Sequence alignment of human RELMβ and mouse HIMF: Alignments of nucleic 
acid cDNA sequence (top) and amino acid sequence (bottom) of human RELMβ (submitted to 
EMBL, Acc.No. AM050721)e and mouse HIMF (NCBI Acc. No. BC029248) employing GAP 
software (HUSAR Bioninformatic package). The nucleic acid sequence identity is 69 %. 
Comparison of the amino acid sequences yields a sequence similarity of 58.6 % and a sequence 
identity of 49.6 %. 
 
3.2.2 Regulation of RELMβ: 
To investigate the expression of RELMβ in different human tissues, human total RNA 
(Premium RNA, Clontech, BD Biosciences, CA, USA) was employed for semi-
quantitative RT-PCR.  HIMF specific and HPRT (house keeping) primers were employed 
for this purpose. Tissue screening of RELMβ expression revealed expression in lung 
(Lu), heart (H), kidney (K) and adrenal gland (A), whereas in brain (B) and liver (L) no 
signal was detectable. Highest expression was observed in intestine (C) (Figure 20-A).  
Expression analysis of RELMβ in different pulmonary cells was performed employing 
A549, SMCPA and FBPA cells. RT-PCR analysis was performed using RNA extracts from 
these cells incubated in normoxic and hypoxic conditions. The RT-PCR results confirmed 
that the mRNA expression of RELMβ was up-regulated during hypoxia. RELMβ was 
detected only in +RT and not –RT samples. The expression profiles were controlled by 
the RT-PCR analysis of a housekeeping gene HPRT (Figure 20-B). 
The real-time RT-PCR analysis for RELMβ mRNA expression was performed using 
RNA extracts from A549, SMCPA and FBPA cells cultured in normoxic (atmospheric) and 
hypoxic (1% O2) condition for 24hr (The medium was pre-equilibrated with the 
respective gas mixture). RELMβ specific and HPRT (housekeeping) primers were 
B 
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RELMß 
200bp 
HPRT 
400bp 
N N N H H H M 
A549 SMCPA FBPA 
C 
employed for this purpose. The quantitative RT-PCR results confirmed that, expression 
of RELMβ is up-regulated in hypoxic condition in these cell types. Pronounced hypoxia 
induced up-regulation of RELMβ expression was observed in A549-epithelial cells and 
SMCPA. While no specific hypoxia mediated induction of RELMβ was observed in FBPA 
cells (Figure 20-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: RELMβ mRNA expression by semi quantitative and quantitative RT-PCR: Total 
RNA for human tissues obtained from Clontech was used to analyse the tissue distribution of 
RELMβ using RT-PCR (A). Total RNA from A549 epithelial cells, SMCPA and FBPA primary 
cells subjected to normoxic and hypoxic conditions were obtained to analyse the hypoxia 
induction of RELMβ using RT-PCR analysis (B) and real-time RT-PCR analysis(C). HPRT 
signals were used as internal controls. Results are shown as the threshold cycle (CT) at which an 
increase of reporter fluorescence (∆Rn) can first be detected. Amounts of RELMβ mRNA were 
normalized to HPRT signals and expressed as 2-∆∆CT. Means ± SE of triplicate samples are 
shown.  
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3.2.3 Cloining full length RELMβ: 
The full-length RELMβ was cloned into the pGEM-T easy plasmid. Sub-cloning of 
RELMβ fragment from pGEM-T easy vectors into pCMV-HA vector was performed as 
mentioned in the methods section.  
 
 
3.2.4 RELMβ western blot: 
Western blot analysis of RELMβ with an HA tag was performed using monoclonal 
mouse antibody against HA (Sigma Aldrich). Cells were transfected with pCMV- 
RELMβ-HA and pCMV-HA vectors using DL and TRDL vectors. Protein preparation 
from the cell lysate was subjected to western blot analysis. The western blot analysis of 
the cell lysate showed that the expression of HA-tagged RELMβ was higher in cells 
transfected with TRDL (Figure 21) over that of DL. Protein isolated from cells 
transfected with pCMV-HA was taken as controls. The corresponding β-actin controls 
were also performed. Thus, transfection and expression of HA-tagged RELMβ was 
controlled by HA Western-blot analysis 
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Figure 21: RELMβ western blot. Cells over-expressed with RELMβ and cellular extracts were 
analyzed by HA-Western-blot showing signals only in case of   RELMβ-HA-plasmid transfected 
cells. [A) A549 cells transfected with RELMβ- TRDL (a), control-TRDL (b), RELMβ-DL (c) 
and control-DL (d). B) SMCPA and C) FBPA cells transfected with RELMβ- TRDL (a), RELMβ-
DL (b) and control-DL (c)]   
 
 
3.2.5 Cell proliferation assay: 
Transfected cells were studied with regard to proliferation by measuring the overall 
cellular mitochondrial respiratory chain activity with MTT assay. Transfection of 
RELMβ containg vectors and the corresponding control vector was performed using 
TRDL vectors. Induction of proliferation by RELMβ observed in all investigated cell 
types was stronger in A549 and SMCPA than FBPA cells (Figure 22). Thus, 
RELMβ appears to be a hypoxic induced mitogenic factor in human lung cells.  
 
 
 
 
 
   
 
  
 
 
 
Figure 22: Cell proliferation. A549, SMCPA and FBPA cells over expressed with RELMβ and 
control vectors were subjected to MTT cell proliferation assay. Means ± SE of n=4 samples are 
shown. 
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4. Discussion: 
4.1 TatRGD mediated gene transfer 
In this study, we have analyzed the potency and mode of transfection of pulmonary cells 
employing the peptide-conjugate TatRGD (TR). HIV-1 derived Tat protein has been 
described to promote the delivery of proteins or nucleic acids (57, 58, 60, 84). Here, we 
utilized a truncated 21-mer Tat peptide corresponding to the region between aminoacid 
residues 43 and 60 consisting of a critical basic aminoacid-stretch (RKKRRQRRR) with 
6 arginines. This domain is supposed to be involved in membrane translocation and in 
nuclear targeting. Particularly, it forms an amphipathic α-helical structure which is 
involved in endocytosis (61). This Tat-peptide was conjugated with a peptide sequence 
displaying an RGD motif. Particularly, this RGD peptide motif has high affinity towards 
integrin receptors (αVβ3, α5β1) expressed on cell surfaces and therefore may improve 
DNA binding to cells. Previous studies have proposed the role of integrin-targeting as an 
efficient pathway for the uptake of synthetic gene delivery vehicles (67). Also, this motif 
has been described to mediate adenovirus uptake (66).  
Since this peptide was labeled with biotin we could perform binding studies between 
DNA and TR. Binding experiments demonstrated affinity between TR and DNA (TRD) 
which is most likely based on interaction between positively charged Arg of Tat and 
DNA phosphate backbone. Also, by these experiments a relevant concentration ratio of 
DNA and TatRGD could be determined.  
Particle size measurements revealed lowering of the size of the TRD complexes upon 
Lipofectamine addition, which is an important feature for successful internalization of 
these complexes. Further, since the utility of such complexes are largely circumscribed 
by their high toxicity, we performed cyto-toxicity assays to derive the optimal 
concentrations of TR for gene transfer in pulmonary cells. 
TR was successfully applied for the improvement of DNA delivery into human 
pulmonary cell-lines and primary cells. Addition of a complex of TR and DNA already 
yielded in significant transgene expression levels in A549 cells. However, when 
combining TR with Lipofectamine, the expression was increased 5-fold over 
Lipofectamine alone (DL) and ~30-fold higher than TRD alone. Therefore, TRD 
complexes were significantly less efficient than DL and TRDL complexes, indicating the 
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likely importance of the lipid component in mediating endosomal escape. This 
observation is consistent with the previous findings on the enhancement of integrin-
mediated transfection of haematopoietic cells with synthetic vector systems (67).  
Similar effect was also observed in primary SMCPA and FBPA cells from pulmonary 
artery, where transfection efficiencies were enhanced by an approximate factor of 2 and 
3-fold, respectively over the DL vector system. 
Tracking of fluorescent labelled DNA by capillary electrophoresis confirmed the 
efficiency of TRDL vectors over DL in A549 and FBPA cells. Further more, the 
transfected luciferase levels were higher with TRDL vector system by 90, 5 and 3.5 folds 
in A549 cell-line, 23, 3 and 1.3 folds in FBPA and 65, 2 and 4 folds in SMCPA primary 
cells, over PEI, DL and CombiMag vector systems respectively.  
Biotinylation of TR also allowed the monitoring of its cellular uptake. One possible 
mechanism to enter cells is mediated by caveoli dependent endocytosis. This pathway has 
been described for several non-enveloped viruses, some bacterial toxins, membrane 
constituents and ligands (78). Caveoli are invaginated plasma membrane domains 
characterized by the presence of the integral membrane protein caveolin-1. They are also 
involved in many endogenous cellular processes like cholesterol homeostasis, 
glycosphingolipid transport and glycosyl-phosphatidyl-inositol anchored protein 
recycling (79). There is also evidence that HIV-1 Tat (67) and HIV-1 virus itself (85) can 
use caveoli for transcytosis across the endothelium. We investigated if TR-D-L 
internalization follows caveoli-mediated pathway. Our confocal microscopic analysis 
revealed co-localization of TatRGD and Caveolin-1 in A549 cells transfected with TRDL 
vector systems. We also observed a time dependent clearance of TR from the cell 
membrane. The cells were permeabilized to observe the cellular internalization of TR. At 
2 h incubation the TR signal was confined to the cell membrane, after 4 h we observed 
moderate amounts of signal in the cytoplasm and after 15 h incubation we observed the 
maximum signal in the cytoplasm. Corresponding time dependant internalization of FAM 
labeled DNA was also observed. Therefore TR containing vector are internalized through 
a slow internalization process similar to that observed with full length Tat internalization 
(67). This slow movement is incompatible with the fast dynamics described for 
constitutive endocytic trafficking of clathrin-coated pits and vesicles (79). Slow dynamics 
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associated with endocytic pathway was recently demonstrated to involve a non-
constitutive and highly stable Caveolin-1 positive endocytic pathway in transfected HeLa 
cells (81).Additional evidences for this mechanism and its dynamics can be found 
elsewhere (82).            
To further demonstrate that TRDL complexes undergo caveoli-mediated internalization, 
caveoli disruption was performed employing the inhibitor methyl-β-cyclodextrin This 
drug has been described to affect caveoli mediated but not clathrin-mediated endocytosis 
(75, 83). Treatment of cells with methyl-β-cyclodextrin drastically decreased the 
transfection efficiency of TatRGD. Interestingly, primary SMCPA that showed less TR 
dependent transfection efficiency also revealed reduced levels of calveolin-1 expression 
when compared to A549 cells in immune-cytochemical analysis. Therefore we suggest a 
strong correlation between TR mediated DNA internalization and the expression pattern 
of caveolins in these cell types. 
In conclusion, the present work indicates that the TatRGD peptide mediates efficient 
gene delivery in human pulmonary cells. In particular, the combination of TatRGD with 
standard cationic lipid based transfection reagent resulted in enhanced gene transfer. The 
improved DNA uptake by TatRGD appears to be mediated by caveoli dependent 
endocytosis. Thus, TatRGD can to be considered as a peptide that favours DNA uptake in 
lung cells and may also be considered as a transfection option for other transfection 
resistant cell types. 
   
 
 
 
 
 
 
 
 
 
        
Chapter 4                                      Discussion 
 71 
4.2 Human RELM-β is a mitogenic factor in lung cells and induced in hypoxia 
 
In this study we have analyzed the gene expression, hypoxic regulation and proliferative 
effects of RELMβ in human lung cells. Our study was inspired by investigations on the 
related HIMF gene in mouse also described in other context as RELMα, or FIZZ1 (72). 
Human RELMβ represents the most homolog gene of mouse HIMF, however is not 
considered as the human ortholog gene of mouse HIMF, which appears not to exist (71). 
Tissue screening of RELMβ expression revealed expression in lung, heart and kidney, 
highest expression in intestine, whereas in brain and liver no signal was detectable. Since 
HIMF plays an important role in hypoxic adaptive processes in lung physiology in 
mouse, we have analyzed the expression, hypoxic regulation and proliferative responses 
of RELMβ in human lung cells. We found strong hypoxic induction of RELMβ in lung 
epithelial A549 cells and primary vascular cells from pulmonary artery. In transfected 
RELMβ overexpressing cells, significant proliferative effects in the studied cells were 
observed. Thus, this study suggests that RELMβ in human is similar regulated as 
described for HIMF in the in vivo mouse experiments and acts as a proliferative factor.  
Consequently, RELMβ in human may play a role in hypoxic induced pulmonary 
remodelling leading to pulmonary hypertension. Also, the induction and proliferative 
responses of RELMβ may play a role in fibrotic lung disease which is associated with 
hypoxia. 
Further findings of HIMF were explored in mice experiments. Beside proliferative 
effects, HIMF was demonstrated to have angiogenic and vasoconstrictive properties (72). 
Additionally, HIMF also was shown to play a role in lung development, by regulation of 
apoptosis and participation in alveolarization and lung maturation (86) and compensatory 
lung growth after pneumectomy (73). Also, HIMF (FIZZ1) was shown to be strongly 
increased during allergic pulmonary inflammation (68). The exploration of these 
characteristics regarding RELMβ in human remains open. So far, functional aspects of 
RELMβ and resistin have been mainly described in mice with respect to resistence to 
insulin (70, 87, 88). Resistin, mainly expressed in adipocytes and RELMβ, expressed 
particularly expressed in epithelial cells from intestine, were demonstrated to mediate 
resistance to insulin leading to increased glucose production.  
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In sum, our study revealed new findings for human RELMβ  as a factor which is induced 
in hypoxia and which exerts proliferative effects. These effects were observed in human 
primary vascular cells from pulmonary artery and a lung epithelial cell line. Thus human 
RELMβ  resembles features as described for the related HIMF described in the lung of 
mice. 
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Perspective: 
 
The present work revealed in it’s first part that TatRGD is an appropriate tool for the 
improvement of transfection of Plasmid-DNA as studied in cultured human lung cells. 
Future perspectives of transfection by  TatRGD may comprise: 
 
1. Application of this technique for theoretical-experimental purpose regarding the 
functional characterization of further human genes in lung cells. 
2. Potential adaptation of TatRGD mediated transfection to ‘small’ nucleic acids as 
antisense oligonucleotides or small interfering RNAs (siRNAs) for the inhibition 
of gene expression. 
3. Employment and adaptation of TatRGD technique for DNA-transfection in vivo 
in animal experiments targeting the lungs by airway access or via pulmonary 
artery. Potential immune responses and toxicity effects are important issues that 
could be examined in this context. 
 
In the second part, this study revealed important new functional and regulatory findings 
of human RELMβ gene in pulmonary cells. These findings on RELMβ raise several 
questions which may be addressed in future studies: 
 
a. Is the regulation of RELMβ in hypoxia directly dependent on hypoxia-inducible-
factors (HIF)? Does the regulatory regions of the RELMβ gene contain hypoxia-
responsive –elements? 
b. What is the mechanism of induction of proliferation by RELMβ: which 
transduction pathway and which second messengers are involved? 
c. Which receptors are responsible for mediating the observed effects of RELMβ?  
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Summary: 
 
The presented study is organized in two sections. In the first part a DNA-transfection 
procedure for human lung cells employing a peptide conjugate has been established and 
the corresponding transfection process characterized. In the second part this new 
transfection strategy has been applied for studying functional aspects of the human 
RELM-β gene. 
 
Cell-lines and primary cells exhibit a varying degree of resistance to DNA transfection 
strategies. In this study, we employed the synthetic peptide TatRGD (TR), composed of 
the HIV-1 derived translocation peptide Tat fused to the integrin binding RGD motif, as a 
tool for improving DNA transfer into human pulmonary cells. Binding experiments 
between DNA and TR and cytotoxicity measurements of TR treated cells were 
undertaken to optimize DNA and TR concentrations for transfection. Addition of a 
complex of TR and DNA (TRD) to A549 cells yielded in significant transgene 
expression.  When combining TRD with Lipofectamine (TRDL), the expression was 
increased by 5-fold over Lipofectamine (DL) and by ~30-fold over TRD mediated 
transfections. Also, in primary smooth muscle cells (SMC) and fibroblasts (FB) derived 
from pulmonary arteries, an increase in TRDL mediated transfection efficiency was 
observed by a factor of ~ 2 and ~ 3 over that of DL. Laser scanning confocal microscopy 
for visualizing TR dependent DNA uptake demonstrated that the internalization of TRDL 
complexes is linked to caveoli in the plasma membrane. Interfering caveoli formation by 
methyl-b-cyclo-dextrin drastically decreased the transfection efficiency by TR. In 
conclusion, the TatRGD peptide mediates efficient gene delivery in human pulmonary 
cells, in particular when combined with standard cationic lipid based transfection reagent. 
The enhancement of DNA uptake by TatRGD is suggested to be mediated by caveoli 
dependent endocytosis.  
 
RELMβ (resistin-like molecule) represents the most related human homologue of mouse 
RELMα also known as hypoxic-induced-mitogenic-factor (HIMF) for which no human 
orthologue gene exist. In this part of the study, we isolated RELMβ cDNA from human 
lung tissue and performed regulatory and functional expression studies with the TatRGD 
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procedure. RELMβ mRNA was upregulated in hypoxia in human lung A549 cell line as 
well as primary cultured adventitial fibroblasts (FB) and smooth muscle cells (SMC) of 
pulmonary artery. Upon transfection of a RELMβ encoding expression plasmid into these 
cells, we observed significant induction of proliferation particularly in SMC and A549 
cells. The results suggest that human RELMβ may contribute to hypoxic induced 
pulmonary vascular remodeling processes or hypoxia related fibrotic lung disease. 
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Zusammenfassung: 
 
Die vorgelegte Studie ist in zwei Abschnitte gegliedert. Im ersten  Teil wird eine DNA- 
Transfektions Prozedur mit Hilfe eines Peptid-Konjugats etabliert und der zugehörige 
Transfektions Prozess charakterisiert. Im zweiten Teil wird diese Transfektions Strategie 
angewendet, um funktionelle Aspekte des humanen RELM-β Gens zu untersuchen. 
 
Zelllinien und primäre Zellen zeigen eine unterschiedliche Resistenz gegenüber DNA- 
Transfektions Methoden. In dieser Studie wurde das synthetische Peptid TatRGD (TR), 
das aus dem von HIV-1 abgeleitetem Translokations Peptid Tat und dem Integrin 
bindenden RGD Motiv  zusammengesetzt ist, genutzt, um den DNA Transfer in humane 
pulmonale Zellen zu begünstigen. Bindungsexperimente zwischen DNA  und TR, sowie 
Zytotoxizitäts Messungen von TR behandelten Zellen wurden durchgeführt, um die zu 
verwendenden DNA und TR Konzentrationen zu optimieren. Zugabe eines Komplexes 
von TR und DNA (TRD) zu A549 Zellen resultierte in signifikanter transgener 
Expression. Die Kombination von TRD und Lipofectamin (TRDL) verstärkte die 
Expression 5-fach gegebenüber Lipofectamin (DL) und 30-fach gegenüber TRD 
vermittelter Transfektion. Ebenso in primär kultivierten glatten Muskelzellen (SMC) und 
adventitialen Fibroblasten (FB), die aus Pulmonalarterien gewonnen wurden, wurde eine 
Steigerung der Transfektionseffizienz um den Faktor 2 bzw. 3 gegenüber DL beobachtet. 
Laser-Scan basierte konfokale Mikroskopie zeigte, dass die TR abhängige DNA 
Aufnahme abhängig von Caveolae in der Plasmamembran ist. Inhibition der Caveolae 
Bildung durch Methyl-b-Cyclo-Dextrin verminderte drastisch die Transfektions Effizienz 
durch TR. Zusammengefasst, vermittelt TatRGD einen effizienten DNA Transfer in 
humane pulmonale Zellen, insbesondere wenn es mit Transfektions Reagenzien, die auf 
kationischen Lipiden basieren, kombiniert wird. Die Steigerung der DNA Aufnahme wird 
vermutlich durch Caveolae-abhängige Endozytose vermittelt. 
 
RELMβ (resistin-like molecule) repräsentiert das am nächsten homologe Gen von 
RELMα der Maus, das auch unter dem Namen HIMF (hypoxic-induced-mitogenic-
factor) bekannt ist, für das aber kein orthologes humanes Gen existiert. In diesem Teil der 
Studie isolierten wir RELMβ cDNA von humanem Lungen Gewebe und führten 
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funktionelle Expressions Studien mittels der TatRGD Methode sowie Untersuchungen zu 
seiner Regulation durch. Wir beobachteten eine Hochregulation von RELMβ mRNA in 
Hypoxie in der epithelialen humanen Lungenzellinie A549 sowie in primär kultivierten 
FB und SMC der Pulmonalarterie. Nach Transfektion der Zellen mit einem 
Expressionsplasmid kodierend für RELMβ beobachteten wir eine signifikante Induktion 
der Proliferation insbesondere in SMC und A549 Zellen. Die Ergebnisse weisen darauf 
hin, dass humanes RELMβ am pulmonal-arteriellen Remodeling Prozess in Hypoxie oder 
an Hypoxie-assozierten fibrotischen Lungenerkrankungen beteiligt sein könnte. 
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